



SEC/12/2026-2027

May 09, 2026

1. National Stock Exchange of India Ltd. Exchange Plaza Plot No. C/1, G Block Bandra -Kurla Complex Bandra (E), Mumbai 400 051 Symbol: KALYANKJIL	2. BSE Limited Corporate Relationship Dept. Phiroze Jeejeebhoy Towers, Dalal Street Mumbai 400001 Maharashtra, India Scrip Code: 543278
--	--

Dear Sir/Madam,

Sub: Audited Standalone and Consolidated Financial Results for the Quarter & Year ended on March 31, 2026 published in newspapers.

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Audited Standalone and Consolidated Financial Results for the quarter & Year ended on March 31, 2026, published in 'Business Standard' (English & Hindi) & 'Deepika' (Malayalam) on May 09, 2026. The Audited Standalone and Consolidated Financial Results for the quarter & year ended on March 31, 2026 is available in the company's website, <http://www.kalyanjewellers.net/>

Thanking You
For **Kalyan Jewellers India Limited**

Jishnu RG
Company Secretary & Compliance Officer

Kalyan Jewellers India Limited
Corporate Office -TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala – 680 002
CIN - L36911KL2009PLC024641
T -0487 2437333 Email – cs@kalyanjewellers.net
WWW.KALYANJEWELLERS.NET

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUJAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products.

More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation.

Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have taken in ₹44 crore each as sales revenue.

"However, the innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability," a Delhi-based endocrinologist told *Business Standard*.

At the same time, tirzepatide, while still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April.

"The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.

Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bari-


atric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower.

"Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. "However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike

Out of breath



SANJAY KOUJAL
New Delhi, 8 May

Respiratory drug sales rose 177 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFM) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer.

According to Pharmarak, respiratory therapy sales rose to ₹1,386 crore in April from ₹1,163 crore Y-o-Y.

The growth was led by cough and cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months.

"Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram.

He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI.

The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files."

The Pentagon says additional documents will be released on a rolling basis.

Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known.

The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

ever confirmed a sighting of alien technology.

Congress ordered the Pentagon to begin releasing decades of files on UFO sightings in 2022 as some members of the military shared encounters with unexplained aircraft.

A small group of Republicans in Congress has pressed for further transparency, accusing the Pentagon of hoarding documents back. A March letter to Rep Anna Paulina Luna demanded 46 UAP videos identified by whistleblowers.

Experts have urged caution around the release of the files, warning that UAP videos are often misinterpreted and mischaracterised by those unfamiliar with advanced military technology.

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator.

The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Ceratratva Innosoch, among others.

The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

You read Business Standard to invest smarter. Read Wirecutter to spend smarter.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.34	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporates), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporates) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products. More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation. Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have risen in ₹44 crore each as sales revenue.



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)


Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year. Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April. "The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators. Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bariatric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower. "Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added. Another doctor said innovator brands are generally considered more reliable in terms of efficacy. However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike

Out of breath



SANJAY KOUAL
New Delhi, 8 May

Respiratory drug sales rose 177 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFPI) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer. According to Pharmarak respiratory therapy sales rose to ₹1,632 crore in April from ₹1,386 crore Y-o-Y. The growth was led by cough and cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months. "Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram. He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI. The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files." The Pentagon says additional documents will be released on a rolling basis. Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known. The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator. The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms. Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Ceraterra InnosTech, among others. The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

You read Business Standard to invest smarter. Read Wirecutter to spend smarter.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.36	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period (comprising profit for the period (after tax) and other comprehensive income (after tax))	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporates), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporates) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUJAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products. More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation. Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have risen in ₹44 crore each as sales revenue.

"However, the innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability," a Delhi-based endocrinologist told *Business Standard*. At the same time, tirzepatide, while still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April. "The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.


Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bari-

atric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower. "Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. "However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike

Out of breath



SANJAY KOUJAL
New Delhi, 8 May

Respiratory drug sales rose 17 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFPI) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer. According to Pharmarak, respiratory therapy sales rose to ₹1,632 crore in April from ₹1,386 crore Y-o-Y. The growth was led by cough and cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months. "Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram. He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI. The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files." The Pentagon says additional documents will be released on a rolling basis. Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known. The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

ever confirmed a sighting of alien technology. Congress ordered the Pentagon to begin releasing decades of files on UFO sightings in 2022 as some members of the military shared encounters with unexplained aircraft. A small group of Republicans in Congress has pressed for further transparency, accusing the Pentagon of hoarding documents back. A March letter to Rep Anna Paulina Luna demanded 46 UAP videos identified by whistleblowers. Experts have urged caution around the release of the files, warning that UAP videos are often misinterpreted and mischaracterised by those unfamiliar with advanced military technology.

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator. The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Ceraterra Innotech, among others. The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

You read Business Standard to invest smarter. Read Wirecutter to spend smarter.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.36	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporates), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporates) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUJAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products. More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation. Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have risen in ₹44 crore each as sales revenue.



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0


*Sum of innovator molecules and generics
Source: Pharmarak

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year. Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April. "The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators. Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bariatric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower. "Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added. Another doctor said innovator brands are generally considered more reliable in terms of efficacy. However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

At the same time, tirzepatide, while still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and

Respiratory drug sales up 18% as asthma cases spike

Out of breath



SANJAY KOUJAL
New Delhi, 8 May

Respiratory drug sales rose 17 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFM) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer. According to Pharmarak respiratory therapy sales rose to ₹1,632 crore in April from ₹1,386 crore Y-o-Y. The growth was led by cough and cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months. "Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram. He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



You read Business Standard to invest smarter. Read Wirecutter to spend smarter.

Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI. The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files." The Pentagon says additional documents will be released on a rolling basis. Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known. The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

ever confirmed a sighting of alien technology. Congress ordered the Pentagon to begin releasing decades of files on UFO sightings in 2022 as some members of the military shared encounters with unexplained aircraft. A small group of Republicans in Congress has pressed for further transparency, accusing the Pentagon of hoarding documents back. A March letter from Rep Anna Paulina Luna demanded 46 UAP videos identified by whistleblowers. Experts have urged caution around the release of the files, warning that UAP videos are often misinterpreted and mischaracterised by those unfamiliar with advanced military technology.

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator. The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms. Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augre AI, BioSky Space Innovations, and Ceratratva Innosoch, among others. The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.34	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporate), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporate) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUJAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products.

More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation.



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have risen in ₹44 crore each as sales revenue.

Generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April.

"The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.


Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bariatric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower.

"Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike

Out of breath



SANJAY KOUJAL
New Delhi, 8 May

Respiratory drug sales rose 177 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFPI) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer.

According to Pharmarak respiratory therapy sales rose to ₹1,386 crore in April from ₹1,163 crore Y-o-Y.

The growth was led by cough and cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months.

"Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram.

He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI.

The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files."

The Pentagon says additional documents will be released on a rolling basis. Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known.

The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator.

The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Ceraterra InnosTech, among others.

The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

You read Business Standard to invest smarter. Read Wirecutter to spend smarter.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.34	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporates), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporates) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

AVIOM India Housing Finance Private Limited

CIN : U65993DL2016PTC291377 website : www.aviom.in. Toll-free helpline number : 1800 120 3466

Worldmark 3, Unit 306A, 3rd Floor, Asset Area No. 7, Hospitality District, Delhi Aerocity, Near Indira Gandhi International Airport, New Delhi-110037, Email: connect@aviom.in

DEMAND NOTICE UNDER SECTION 13(2) OF SARFESI ACT

A notice is hereby given that the following APPLICANT/ COAPPLICANT (S)/GUARANTOR have defaulted in the repayment of principal and interest of the loans facility obtained by them from the AVIOM INDIA HOUSING FINANCE PRIVATE LIMITED and the loans have been classified as Non-Performing Assets (NPA). The notices were issued to them under Section 13(2) of Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 on their last known address and they have been returned unacknowledged and as such they are hereby informed by way of this public notice. The APPLICANT/COAPPLICANT(S)/GUARANTOR/whenever applicable hereby called upon to make payment of outstanding amount within 60 days from the date of publication of this notice, failing which further steps will be taken after expiry of 60 days from the date of the notice under sub-section (4) of Section 13 of Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002. The APPLICANT/COAPPLICANT(S)/GUARANTOR attention is invited to provisions of Sub-section (8) of Section 13 of the Act, in respect of time available to redeem the secured assets.

Sl. No.	APPLICANT/ COAPPLICANT (S)/GUARANTOR NAME & ADDRESS	PROPERTY ADDRESS	Date of Demand Notice/ Total Outstanding Date	DATE OF IPA CLASSIFICATION	HL Code	OUTSTANDING AMOUNT
81	RAJKIRAN BALA HARRAPUR 392 KURUKSHETRA VILLAGE- HARYAPUR, THAMESAR HARYANA, HAR, 136131, PRINCE PRINCE, JAMNA DASS, NARINDER KAUR ; ALL AT HARYAPUR/HARRAPUR 392 SIRSALA THAMESAR HARYANA 136131	58539001000000684, Thamesar Thamesar Haryana 136131	21-Mar-26	08-11-2024	HL000000094766	₹ 6,73,477.91
82	PREMI DEVI ; 241 CHAND SAULI 116AMBALUJEOJI CHANDSAULI AMBALA CITY HARYANA 134203	VII Chandsauli Ambala Shiv Mandir Ambala City Haryana 134203	21-Mar-26	08-10-2024	HL000000096952	₹ 3,27,480.63
83	NANDI NANDI ; VILL BALU KATHAL, VILL KALAVAT, HARYANA, HAR, 136117, CO-APP (s): RAHSARAN RAMSARAN, SONU SONU ; ALL AT: VILL BALU, KATHAL/VILL BALU, KATHAL, HARYANA 136117	Khevat No. 1395 Ragnia Path Neerby Pond Kathal Haryana 136117	21-Mar-26	08-02-2024	HL000000096679	₹ 7,24,289.59
84	SUMAN RANI ; VILLAGE UPLANA BARARA THAKAR PURA AMBALA, UPLANA, BARARA, HARYANA, HAR, 133203, CO-APP (s): BARKHA RANI, GURMEET SINGH ; ALL AT: KALA AMB NAHAU HARYANA 173030	VII Uplana Ambala Shiv Mandir Ambala Haryana 133203	21-Mar-26	09-12-2024	HL000000097567	₹ 3,00,969.97
85	PARAMJEET KAUR ; VILLAGE ULJAL MAJRI P O KATHE MAJRA 81 AMBALA, ULJAL MAJRI, PANCHKULA, HARYANA, HAR, 134203, CO-APP (s): SANJEEV KUMAR ; AMBALA PANCHKULA HARYANA 134203	VII Uljal Majri Ambala Dharanmahal Ambala City Haryana 134203	21-Mar-26	08-02-2024	HL000000098780	₹ 6,83,992.84
86	RENA DEVI ; VILLAGE UPLANA BARARA AMBALA, UPLANA, BARARA, HARYANA, HAR, 133200, CO-APP (s): RAVINDER KUMAR ; NARAINGARH AMBALA CITY HARYANA 134203	VII Uplana Barara Shiv Mandir Barara Haryana 133203	21-Mar-26	09-12-2024	HL000000098784	₹ 4,37,659.57
87	RENU RENU ; VILL SIRTA, KATHAL, VILL SIRTA, KATHAL, HARYANA, HARYANA, 136027, CO-APP (s): DEEPAK DEEPAK ; VILL SIRTA, KATHAL/VILL SIRTA, KATHAL, KATHAL, HARYANA 136027	VII Sirta Near Ravidas Mandir Kathal Haryana 136027	21-Mar-26	08-11-2024	HL000000098300	₹ 448,570.75
88	DARSHINA DARSHINA ; DURGA COLONY KALA AMB CERA 190 AMBALA, KALA AMB, PANCHKULA, HARYANA, HAR, 134203, CO-APP (s): VINOD KUMAR ; CERA (190) AMBALA PANCHKULA, HARYANA 134203	Durga Colony Kala Amb Govt School Naramangari Haryana 134203	21-Mar-26	08-11-2024	HL000000099880	₹ 5,05,381.10
89	NISHA NISHA ; VILL CHHOT KATHAL, VILL CHHOT, KATHAL, HARYANA, HAR, 136027, CO-APP (s): SATINDER KUMAR ; VILL CHHOT, KATHAL/VILL CHHOT, KATHAL, KATHAL, HARYANA 136027	VII Chhot Near Datta Khera Kathal Haryana 136027	21-Mar-26	08-10-2024	HL000000099240	₹ 6,65,818.48
90	ANJUN ANJUN ; RAIPUR 147 YAMUNANAGAR, YAMUNA NAGAR, RAIPUR, YAMUNA NAGAR, HARYANA, HAR, 135001, CO-APP (s): ASLAM ASLAM, SAMREYAN SAMREYAN ; ALL AT YAMUNANAGAR/YAMUNA NAGAR YAMUNANAGAR HARYANA 135001	Village Raipur Yamunanagar Ahmed General Store Yamuna Nagar Haryana 135001	21-Mar-26	08-11-2024	HL000000010294	₹ 5,56,345.51
91	AFSANA PERWEEJA ; EKTA VIHAR, JAIPUR DELHI, SURYA VIHAR PART - 3 STREET NO. 11 NEEM WALI GALI ADWAINPUR, NEW DELHI, HARYANA, HAR, 110044, CO-APP (s): MOHD SHOABS ALJAM ; GURGANODIYD VHKAR DFL PH-1 HARYANA 121013	Surya Vihar Part-3, Street No. Fandaoad Haryana 121013	21-Mar-26	08-11-2024	HL000000010679	₹ 3,35,138.97
92	PARVATI DEV ; SAFEHRA (95) AMBALA, SAFEHRA, AMBALA, HARYANA, HAR, 133104, CO-APP (s): PREET KAUR ; VILLAGE SAMBALKHADISTI AMBALA AMBALA HARYANA 133104	VII Safehra Ambala Guruwara Ambala Haryana 133104	21-Mar-26	08-11-2024	HL0000000109435	₹ 4,11,454.63
93	SUBHAM KUMAR ; VILLAGE SAHEHRA (95) AMBALA, SAFEHRA, AMBALA, HARYANA, HAR, 133104, CO-APP (s): MEHANDI HASAN ; SAFEHRA AMBALA AMBALA HARYANA 133104	VII Safehra Ambala Guruwara Ambala Haryana 133104	21-Mar-26	08-11-2024	HL0000000109467	₹ 3,00,067.21
94	GULSHAN AARA ; SAFEHRA (95) AMBALA, SAFEHRA, AMBALA, HARYANA, HAR, 133104, CO-APP (s): MEHANDI HASAN ; SAFEHRA AMBALA AMBALA HARYANA 133104	VII Safehra Ambala Guruwara Ambala Haryana 133104	21-Mar-26	09-12-2024	HL0000000109672	₹ 1,62,673.41
95	REKHA DEV ; 137 WARD NO 2, BARTHAL, VILLAGE BARTHAL, NIGDHU, HARYANA, HAR, 132157, CO-APP (s): SURESH KUMAR ; 137 WARD NO 2 BARTHAL, NIGDHU, HARYANA 132157	Bartthal Nighdu Haryana 132157	21-Mar-26	08-11-2024	HL000000013269	₹ 5,15,812.53
96	BANO BANO ; VILLAGE BIEBUPUR AMADALPUR (395) YAMUNANAGAR, BIEBUPUR, AMBALA, HARYANA, HAR, 135101, CO-APP (s): FARUK FARUK, AKHTAR AKHTAR ; ALL AT: YAMUNANAGAR AMBALA HARYANA 135101	VII Biebur Yamunanagar Masjid Ambala Haryana 135101	21-Mar-26	08-11-2024	HL000000013428	₹ 4,79,583.03
97	KARNAL KAUR ; BHARELI PANCHKULA, BHARELI AMBALA, HARYANA, HAR, 134116, CO-APP (s): RAVINDER KUMAR ; VILLAGE BHARELI PANCHKULA AMBALA HARYANA 134116	VII Bhareli, Barwala Sirti Doydas Mandir Ambala Haryana 134116	21-Mar-26	08-10-2024	HL000000013427	₹ 4,79,583.03
98	SHABNAM ; SALEMPIUR BANGAR YAMUNANAGAR, YAMUNANAGAR, SALEMPIUR BANGAR, YAMUNANAGAR, HARYANA, HAR, 135021, CO-APP (s): IRAM KHAN ; YAMUNANAGAR YAMUNA NAGAR HARYANA 135021	Village Salempur Banjar Yamunanagar Nr Govt School Yamuna Nagar Haryana 135021	21-Mar-26	08-11-2024	HL000000013428	₹ 96,019.62
99	PRIYA ; BARTHAL, BARTHAL, NIGDHU, HARYANA, HAR, 132157, CO-APP (s): SAWAN KUMAR ; VILLAGE BARTHAL KARNAL NIGDHU HARYANA 132157	Bartthal Nighdu Haryana 132157	21-Mar-26	08-11-2024	HL000000015071	₹ 4,70,663.48
100	KRISHNA ; GALI NO 1 SHAKTI NAGAR, KATHAL, KATHAL, HARYANA, HAR, 136027, CO-APP (s): SARWAN, PARVEEN ; ALL AT: GALI NO 1 SHAKTI NAGAR GALI NO 1 SHAKTI NAGAR KATHAL, HARYANA 136027	Gali No 1 Shakti Nagar/Kathal Palu Ram K Kothi Kathal Haryana 136027	21-Mar-26	08-11-2024	HL000000015137	₹ 4,29,759.71
101	NISHA DEVI ; SALEMPIUR BANGAR (321) SALEMPIUR BANGAR YAMUNANAGAR, SALEMPIUR BANGAR, CHHACHHRAULI, HARYANA, HAR, 135013, CO-APP (s): RAVINDER KUMAR ; SALEMPIUR BANGAR YAMUNANAGAR HARYANA 135013	VII Salempur Banjar Yamunanagar Kheda Mandir Yamuna Nagar Haryana 135013	21-Mar-26	08-11-2024	HL000000016020	₹ 6,85,615.48
102	RANI ; CHANDOLI NARANANGARI AMBALA, YAMUNA NAGAR, CHANDOLI NARANANGARI, AMBALA CITY, HARYANA, HAR, 134203, CO-APP (s): YADIPAL YADIPAL ; YAMUNANAGAR YAMUNA NAGAR NARANANGARI HARYANA 134203	Village Chandoli Ambala Kheda Mandir Ambala Haryana 134203	21-Mar-26	08-10-2024	HL000000017862	₹ 2,96,771.27
103	ASHIYA ; MOHRIMANDI HARYANA NAGAR, YAMUNANAGAR, MOHRIMANDI HARYANA, HAR, 135133, CO-APP (s): SANJU ; YAMUNA NAGAR YAMUNA NAGAR JAGADHRI HARYANA 135133	Village Mohri Yamunanagar Nr Govt School Yamuna Nagar Haryana 135133	21-Mar-26	09-12-2024	HL000000018814	₹ 2,25,425.75
104	SALMA ; NAGAL PATTI 5 KHIZRABAD EAST YAMUNANAGAR, NAGAL PATTI MILK KHIZRABAD, YAMUNA NAGAR, HARYANA, HAR, 135021, CO-APP (s): NAJAR, ASIK ; ALL AT: NAGAL PATTI YAMUNANAGAR HARYANA 135021	VII Nagal Patti Milk Khizrabad Masjid Yamuna Nagar Haryana 135021	21-Mar-26	08-11-2024	HL000000019212	₹ 3,71,252.02
105	RAJINDER KAUR ; LAKH HALLA 179 NARANANGARI AMBALA, LAKH HALLA, PANCHKULA, HARYANA, HAR, 134203, CO-APP (s): GURDIP ; LAKH HALLA AMBALA PANCHKULA HARYANA 134203	Village Lakhnara Naranangar Govt School Ambala City Haryana 134203	21-Mar-26	08-10-2024	HL000000020977	₹ 5,54,480.24
106	SHAMSIDA ; TAHARPUR 28 YAMUNANAGAR, TAHARPUR, CHHACHHRAULI, HARYANA, HAR, 135103, CO-APP (s): INTJAR ; TAHARPUR CHHACHHRAULI HARYANA 135103	VII Tahapur Chachrauli Masjid Ambala Haryana 135103	21-Mar-26	09-12-2024	HL000000020978	₹ 3,12,409.98
107	ANJU ; PAHARI PUR SADHNAUR YAMUNA NAGAR, YAMUNA NAGAR VILLAGE PAHARI PUR, YAMUNANAGAR, HARYANA, HAR, 133204, CO-APP (s): KARAMEER ; YAMUNANAGAR YAMUNA NAGAR YAMUNA NAGAR HARYANA 133204	VII Pahari Pur Yamuna Nagar Gurudwara Yamuna Nagar Haryana 133204	21-Mar-26	08-10-2024	HL000000020947	₹ 3,45,434.42
108	MEENAKSHI RANI ; MANDI YAMUNA NAGAR, YAMUNA NAGAR, VILLAGE MANDI, CHHACHHRAULI, HARYANA, HAR, 135101, CO-APP (s): BEER SINGH ; YAMUNA NAGAR YAMUNA NAGAR CHHACHHRAULI HARYANA 135101	Village Mandi Yamuna Nagar Kheta Yamuna Nagar Haryana 135021	21-Mar-26	08-11-2024	HL000000020911	₹ 4,52,309.28
109	KRISHNA DEVI ; KALAMB AMBALA CITY, HARYANA, HAR, 134203, CO-APP (s): BINTU RAM ; KALAMB AMBALA CITY HARYANA 134203	Kala Amb Kala Amb Sisco Pvt Ltd Kalka Haryana 134102	21-Mar-26	08-02-2025	HL000000021083	₹ 2,92,293.07
110	HANSA DEVI ; RUKARE CHIN AMBALA, YAMUNA NAGAR, RUKADI AMBALA, HARYANA, HAR, 133202, CO-APP (s): MALANG SINGH, KAJAL RANI ; VIKASH SINGH MANGLA TOPWAL; ALL AT: YAMUNANAGAR YAMUNA NAGAR AMBALA HARYANA 133202	Village Rukadi Yamuna Nagar Alta Chaiki Yamuna Nagar Haryana 133202	21-Mar-26	08-10-2024	HL000000021612	₹ 3,09,918.12
111	SHUFIYANA ; SAFI PUR YAMUNANAGAR, BUCI AMBALA, HARYANA, HAR, 133204, CO-APP (s): AKHAB ; BUCI AMBALA HARYANA 133204	VII Bipi Saduara Yamunanagar Govt School Yamuna Nagar Haryana 133204	21-Mar-26	08-11-2024	HL000000023490	₹ 4,40,381.22
112	SHANTOSH ; 202 KIRKONDI PANCHKULA, KIRKONDI AMBALA, HARYANA, HAR, 133104, CO-APP (s): KIRKONDI ; KIRKONDI AMBALA HARYANA 133104	393 Gulgura, Raipur Rast Shiv Mandir Ambala Haryana 134118	21-Mar-26	08-11-2024	HL000000026451	₹ 4,45,084.71
113	KOMAL RANI ; MILK SUKH MANDI HARYANA NAGAR, MILK SUKH AMBALA, HARYANA, HAR, 135003, CO-APP (s): ANIL SINGH ; MILK SUKH MANDI HARYANA NAGAR AMBALA HARYANA 135003	VII Milk Sukh Bilsapur Sant Ravidas Mandir Yamuna Nagar Haryana 135003	21-Mar-26	08-10-2024	HL000000027625	₹ 6,60,518.25
114	RAMJEET LAL, TARSEEM ; ALL AT: YAMUNANAGAR YAMUNANAGAR HARYANA 135003	VII Ramjeet Lal, Tarseem Yamunanagar Haryana 135003	21-Mar-26	08-11-2024	HL000000028311	₹ 4,52,309.28
115	PARAMJEET KAUR ; JANDHARI 240 KURUKSHETRA, JANDHARI, SHAHABAD, HARYANA, HAR, 136135, CO-APP (s): PAWAN KUMAR, VIKASH ; ALL AT: JANDHARI SHAHABAD HARYANA 136135	VII Jandhari Shahabad Gurudwara Shahabad Haryana 136135	21-Mar-26	08-12-2024	HL000000028227	₹ 4,42,375.41
116	NAZM KHATUN ; PULI CHANDU 348 YAMUNANAGAR, PULI CHANDU, JAGADHRI, HARYANA, HAR, 135103, CO-APP (s): SIKHARU LAL ; MUSTAFABAD, JAGADHRI HARYANA 135103	VII Kulkhondi Jagadhi Shiv Mandir Ambala Haryana 133103	21-Mar-26	08-12-2024	HL000000028389	₹ 3,49,275.20
117	AASHMA ; YAKHUPUR PIRI MAURA YAMUNANAGAR, YAKHUPUR, AMBALA, HARYANA, HAR, 135108, CO-APP (s): RUSKAR ALI ; PIRI MAURA AMBALA HARYANA 135108	VII Yakhupur Chachrauli Masjid Yamuna Nagar Haryana 135108	21-Mar-26	08-10-2024	HL000000024864	₹ 3,17,283.85
118	JASVINDER JASVINDER ; VILLAGE RATHAL LAHAPUR YAMUNA NAGAR, RATHAL AMBALA HARYANA, HAR, 133204, CO-APP (s): SATNAM RATHAL ; JAMBALA HARYANA 133204	VII Rathal Sadhuara Goga Masjid Ambala Haryana 133204	21-Mar-26	08-11-2024	HL000000025088	₹ 5,01,852.44
119	SANGEETA ; VILLAGE HARYOLI RAIPUR RANI, HARYOLI, PANCHKULA, HARYANA, HAR, 134202, CO-APP (s): BALDEV SINGH ; RAIPUR RANI PANCHKULA HARYANA 134202	VII Haryoli Raipur Rani Sant Ravidas Mandir Panchkula Haryana 134204	21-Mar-26	08-11-2024	HL000000025957	₹ 4,09,237.37
120	NEELAM DEVI ; RAIPUR JAT YAMUNANAGAR, AMBALA, HARYANA, HAR, 135102, CO-APP (s): PARDEEP KUMAR ; RAIPUR JAT JAGADHRI HARYANA 135102	VII Rampur Jatian Jagadhi Bus Stand Jagadhi Haryana 135102	21-Mar-26	08-11-2024	HL000000025182	₹ 4,09,237.37
121	PARRAKO ; VILLAGE MANGLORE JAGADHRI, HARYANA, HAR, 135102, CO-APP (s): SATPAL, PREM KUMAR, PRABHU DAYAL SINGH ; ALL AT: MANGLORE AMBALA HARYANA 135102	VII Manglore Bilsapur Sant Ravidas Mandir Jagadhi Haryana 135102	21-Mar-26	08-11-2024	HL000000026344	₹ 5,83,521.83
122	KAMLESH DEV ; VILLAGE BHASKAR NARANANGAR, PANCHKULA, HARYANA, HAR, 134202, CO-APP (s): MANOJ KUMAR ; PANCHKULA AMBALA HARYANA 134202	Badagang Naranangar Panchkula Haryana 134202	21-Mar-26	09-12-2024	HL000000027675	₹ 3,29,702.38
123	MANJEET KAUR ; VILLAGE THASARA CHHACHHRAULI AMBALA, HARYANA, HAR, 133204, CO-APP (s): SHYAM LAL ; YAMUNANAGAR AMBALA HARYANA 133204	Thasara Ambala Haryana 133204	21-Mar-26	08-10-2024	HL000000027851	₹ 6,17,418.05
124	SUNITA DEVI ; DHAKDEVI, SAHARANPUR, SAHARANPUR, UTTAR PRADESH, HAR, 247001, CO-APP (s): NARESH KUMAR ; SAHARANPUR SAHARANPUR SAHARANPUR HARYANA 247001	Village Dhakdevi Saharanpur Ganes Mandir Saharanpur Uttar Pradesh 247001	21-Mar-26	08-10-2024	HL000000028526	₹ 60,550.22
125	AFSANA ; DHAKDEVI, SAHARANPUR, AMBALA, HARYANA, HAR, 135101, CO-APP (s): ABID HASAN ; YAMUNANAGAR AMBALA HARYANA 135101	Mukundpur Ambala Haryana 135101	21-Mar-26	08-11-2024	HL000000028637	₹ 3,40,756.93
126	JASVINDER KAUR ; VILLAGE MUKANDPUR AMBALA, AMBALA CITY, HARYANA, HAR, 134202, CO-APP (s): ASHOK KUMAR ; SHAHZADPUR AMBALA CITY HARYANA 134202	Mukundpur Ambala City Haryana 134202	21-Mar-26	08-11-2024	HL000000028624	₹ 3,83,690.69
127	MARZEENA ; VILLAGE TEWAR YAMUNANAGAR, AMBALA, HARYANA, HAR, 133204, CO-APP (s): IKRAN, JANNAT ; ALL AT: YAMUNANAGAR AMBALA HARYANA 133204	Tewar Yamuna Nagar Haryana 133204	21-Mar-26	08-11-2024	HL000000028892	₹ 4,53,358.93
128	SUBISH KUMAR ; YAMUNANAGAR, AMBALA, HARYANA, HAR, 133202, CO-APP (s): PARVEEN KUMAR ; YAMUNANAGAR YAMUNA NAGAR AMBALA HARYANA 133202	Fatehpur Yamuna Nagar Gurudwara Ravidas Mandir Yamuna Nagar Haryana 133202	21-Mar-26	08-12-2024	HL000000028843	₹ 3,23,713.57
129	JAMIDA ; KALYANPUR ATARI YAMUNA NAGAR, AMBALA, HARYANA, HAR, 133204, CO-APP (s): KAMALDEW ; YAMUNANAGAR AMBALA HARYANA 133204	Kalyanpur Yamuna Nagar Haryana 133204	21-Mar-26	08-11-2024	HL000000029574	₹ 4,83,386.41
130	RAJIEET KAUR ; VILLAGE HAIDPUR YAMUNA NAGAR, YAMUNANAGAR, HARYANA, HAR, 135103, CO-APP (s): TEK SINGH, KARNAL SINGH ; ALL AT: YAMUNANAGAR YAMUNA NAGAR HARYANA 135103	Haidpur Yamuna Nagar Haryana 135103	21-Mar-26	08-11-2024	HL000000029619	₹ 4,45,381.34

Date : 08-05-2026 Place : HARYANA Sd/- Authorised Officer AVIOM INDIA HOUSING FINANCE PRIVATE LIMITED

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026	31 December 2025	31 March 2025	31 March 2025		31 March 2026	31 December 2025	31 March 2025	31 March 2026	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	
2 Net profit (loss) for the period before tax after exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	
3 Net profit (loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.36	2,506.05	18,019.91	
4 Net profit (loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJEEV KOUAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products.

More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation.

Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have risen in ₹44 crore each as sales revenue.

"However, the innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability," a Delhi-based endocrinologist told *Business Standard*.

At the same time, tirzepatide, while still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April.

"The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.

Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bari-


atric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower.

"Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. "However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike

Out of breath



SANJEEV KOUAL
New Delhi, 8 May

Respiratory drug sales rose 177 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFPI) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer.

According to Pharmarak respiratory therapy sales rose to ₹1,632 crore in April from ₹1,386 crore Y-o-Y.

The growth was led by cough and cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months.

"Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram.

He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, Nasa and the FBI.

The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files."

The Pentagon says additional documents will be released on a rolling basis.

Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known.

The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator.

The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augre AI, BioSky Space Innovations, and Ceratratva Innosoch, among others.

The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

You read Business Standard to invest smarter. Read Wirecutter to spend smarter.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.36	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporates), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporates) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUJAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products.

More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation.

Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmark. Of this, both innovator and generic semaglutide have risen in ₹44 crore each as sales revenue.

"However, the innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability," a Delhi-based endocrinologist told *Business Standard*.

At the same time, tirzepatide, while still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmark

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 20,000 units sold in March to 28,000 units in April.

"The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmark. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.


Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bariatric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower.

Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. "However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike

Out of breath



SANJAY KOUJAL
New Delhi, 8 May

Respiratory drug sales rose 17 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFM) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer.

According to Pharmark respiratory therapy sales rose to ₹1,632 crore in April from ₹1,386 crore Y-o-Y.

The growth was led by cough-and-cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmark. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months.

"Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonary and critical care, CK Birla Hospital, Gurugram.

He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI.

The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files." The Pentagon says additional documents will be released on a rolling basis. Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known.

The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

ever confirmed a sighting of alien technology.

Congress ordered the Pentagon to begin releasing decades of files on UFO sightings in 2022 as some members of the military shared encounters with unexplained aircraft.

A small group of Republicans in Congress has pressed for further transparency, accusing the Pentagon of hoarding documents back. A March letter to Rep Anna Paulina Luna demanded 46 UAP videos identified by whistleblowers.

Experts have urged caution around the release of the files, warning that UAP videos are often misinterpreted and mischaracterised by those unfamiliar with advanced military technology.

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator.

The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albattross, which has developed an energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Coranatra Innotech, among others.

The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

निदेशालय, सूचना, लोक सम्पर्क एवं भाषा, हरियाणा

आजादी की पहली लड़ाई का शहीद स्मारक, अम्बाला कैंट

'निविदा सम्बन्धी सूचना'

1857 की कान्ति की याद में वीर जवानों की बहादुरी एवं शहादत को नमन करने के लिए अम्बाला कैंट में (अम्बाला कैंट-दिल्ली) नेशनल हाईवे-44 पर 'आजादी की पहली लड़ाई का शहीद स्मारक' का निर्माण किया जा रहा है। यह एशिया का सबसे बड़ा स्मारक बनाया जा रहा है जिसमें प्रतिदिन हजारों लोगों का आवागमन होगा।

स्मारक के प्रथम तल पर 08 Food Court स्थित है। एक Food Court का Carpet Area 204.87 वर्ग फुट है तथा प्रत्येक Food Court के सामने 08 वर्ग फुट का ओपन एरिया उपलब्ध होगा।

विभाग द्वारा 07 Food Court को लीज पर देने हेतु <https://etenders.hry.nic.in> पर निविदा लगाकर बोलियां आमंत्रित की गई हैं जिसकी अंतिम तिथि 01 जून, 2026 सायं : 04.00 बजे तक है। इस निविदा की ID- 2026_HRY_520364_1 है तथा इसके दस्तावेज व अन्य शर्तें उक्त वेबसाइट से डाउनलोड की जा सकती हैं। अगर कोई बोलौदाता Food Court देखना चाहता है तो वह किसी भी दिन सायं 05.00 बजे से पहले देख सकता है।

पता: सूचना, लोक सम्पर्क एवं भाषा विभाग, हरियाणा, एस.सी.ओ. नं. 200-201, सेक्टर-17 सी, चण्डीगढ़, फोन नं. 0172-5046246
ई-मेल: directorsahaedsamarak@gmail.com

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnunnam, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone			Consolidated						
	For the quarter ended			For the year ended		For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Unaudited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Unaudited)	
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit (loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit (loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.36	2,506.05	18,019.91	9,596.01
4 Net profit (loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporate), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporate) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of the BOARD OF DIRECTORS

S.S. Kalyanaraman
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUJAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products.



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation. Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have taken in ₹44 crore each as sales revenue.

"However, the innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability," a Delhi-based endocrinologist told *Business Standard*.

At the same time, tirzepatide, while still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April.

"The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.

Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bariatric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower.


"Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. "However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike

Out of breath

Respiratory drug sales in April 2026
Figures in brackets are % chg



SANJAY KOUJAL
New Delhi, 8 May

Respiratory drug sales rose 17 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFPI) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer. According to Pharmarak, respiratory therapy sales rose to ₹1,632 crore in April from ₹1,386 crore Y-o-Y.

The growth was led by cough and cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months. "Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram. He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI.

The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files."

The Pentagon says additional documents will be released on a rolling basis. Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known.

The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

ever confirmed a sighting of alien technology.

Congress ordered the Pentagon to begin releasing decades of files on UFO sightings in 2022 as some members of the military shared encounters with unexplained aircraft.

A small group of Republicans in Congress has pressed for further transparency, accusing the Pentagon of hoarding documents back. A March letter to Rep Anna Paulina Luna demanded 46 UAP videos identified by whistleblowers.

Experts have urged caution around the release of the files, warning that UAP videos are often misinterpreted and mischaracterised by those unfamiliar with advanced military technology.

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator.

The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Ceraterra InnosTech, among others.

The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

You read Business Standard to invest smarter. Read Wirecutter to spend smarter.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.34	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporate), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporate) and on the Company's website.



For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUJAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products.

More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation.

Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have risen in ₹44 crore each as sales revenue.

"However, the innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability," a Delhi-based endocrinologist told *Business Standard*.

At the same time, tirzepatide, while still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April.

"The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.

Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bari-


atric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower.

"Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. "However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike

Out of breath



SANJAY KOUJAL
New Delhi, 8 May

Respiratory drug sales rose 17 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFPI) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer.

According to Pharmarak, respiratory therapy sales rose to ₹1,632 crore in April from ₹1,386 crore Y-o-Y.

The growth was led by cough and cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months.

"Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram.

He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI.

The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files."

The Pentagon says additional documents will be released on a rolling basis.

Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known.

The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

ever confirmed a sighting of alien technology.

Congress ordered the Pentagon to begin releasing decades of files on UFO sightings in 2022 as some members of the military shared encounters with unexplained aircraft.

A small group of Republicans in Congress has pressed for further transparency, accusing the Pentagon of hoarding documents back. A March letter to Rep Anna Paulina Luna demanded 46 UAP videos identified by whistleblowers.

Experts have urged caution around the release of the files, warning that UAP videos are often misinterpreted and mischaracterised by those unfamiliar with advanced military technology.

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator.

The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Ceraterra Innosoch, among others.

The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

You read Business Standard to invest smarter. Read Wirecutter to spend smarter.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.34	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporates), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporates) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJEEV KOUAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products.

More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation.

Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have innovated in ₹44 crore each as sales revenue.

"However, the innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability," a Delhi-based endocrinologist told *Business Standard*.

At the same time, tirzepatide, whilst still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 20,000 units sold in March to 32,000 units in April.


"The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.

Sukhvinder Singh Saggu, director for minimal access, gastrointestinal and bariatric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower.

"Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. "However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike



SANJEEV KOUAL
New Delhi, 8 May

Respiratory drug sales rose 177 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IPM) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer.

According to Pharmarak, respiratory therapy sales rose to ₹1,632 crore in April from ₹1,386 crore Y-o-Y.

The growth was led by cough and cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months.

"Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonary and critical care, CK Birla Hospital, Gurugram.

He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.

Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI.

The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files."

The Pentagon says additional documents will be released on a rolling basis.

Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known.

The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance (IDTA) India Deep Tech Accelerator.

The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed an energy-efficient liquid desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Corantra V Innovtech, among others.

The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

BANKING STRENGTH BEHIND UTTAR PRADESH'S GROWTH: BANK OF BARODA'S EXPANDING CONTRIBUTION

Uttar Pradesh, one of India's fastest-growing state economies, is witnessing rapid transformation driven by infrastructure development, industry, agriculture, MSME and financial inclusion. This growth has been supported by the banking sector, with Bank of Baroda playing a key role in the economic expansion, GSDP growth and social security coverage across the state.



Mr. Shailendra Kumar Singh, General Manager & Zonal Head, Bank of Baroda, Lucknow Zone

Bank of Baroda serves customers through a wide network of 21,364 touch points across all 75 districts of Uttar Pradesh, supported by digital banking platforms that provide seamless access to financial products and services. The Bank's vision aligns with the aspirations of a diverse customer base and focuses on trust, accessibility, and financial security.

The Bank vision aligns with the aspirations of a diverse customer base and focuses on trust, accessibility and financial security

Through financial inclusion drives and digital banking outreach, the Bank is strengthening the formal financial ecosystem, reducing dependence on informal credit, and improving grassroots productivity.

The Bank is leveraging Bank Sakshis to expand doorstep banking services in rural and underserved areas. During FY 2025-26, it strengthened financial inclusion through 6 lakh Pradhan Mantri Jan Dhan Yojana (PMJDY) accounts, 2.11 lakh Atal Pension Yojana (APY), 7 lakh Pradhan Mantri Jeevan Jyoti Bima Yojana (PMJJBY), 15 lakh Pradhan Mantri Suraksha Bima Yojana (PMSBY), and 19,000 Sukanya Samridhhi Accounts (SSA).

Bank of Baroda has emerged as a Top Performer under the Mukhyamantri Yuva Udyami Vikas Yojana (CM-YUVA), achieving 148% of its target and supporting entrepreneurship and local employment generation. The Bank also offers digital financing solutions up to ₹5 lakh for farmers to adopt modern agricultural equipment and scientific farming practices, helping improve productivity and farm income.

One of the Bank's most impactful initiatives is the insurance coverage embedded in salary account packages, especially for serving personnel, pen-



sions and family pensioners of the Uttar Pradesh Police. Over the last three years, the Bank has settled insurance claims exceeding ₹275 crore for UP Police personnel and families, providing critical financial support during difficult times. The Bank also offers specialised salary packages for State Government employees and has entered into MoUs with several state departments. These initiatives improve financial convenience and encourage economic activity through easier access to banking and credit services.

As one of India's leading public sec-

and solar rooftop projects, and green infrastructure bonds supporting sustainable development.

Bank of Baroda's contribution extends beyond conventional banking. By integrating credit expansion, financial inclusion, digital transformation, and social security, the Bank is directly supporting Uttar Pradesh's inclusive growth agenda. As Uttar Pradesh advances towards becoming a trillion-dollar economy, Bank of Baroda will continue to play a transformative role as enablers of sustainable and equitable economic progress in the state.

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnkunnam, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewelers.net | Website: www.kalyanjewelers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone				Consolidated					
	For the quarter ended		For the year ended		For the quarter ended		For the year ended			
	31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025	31 March 2026	31 December 2025	31 March 2025		
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit (loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit (loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.36	2,506.05	18,019.91	9,596.01
4 Net profit (loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period (comprising profit for the period (after tax) and other comprehensive income (after tax))	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporate), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporate) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of the BOARD OF DIRECTORS
T.S. Kalyanaraman
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUJAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products.

More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation.

Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have risen in ₹44 crore each as sales revenue.

"However, the innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability," a Delhi-based endocrinologist told *Business Standard*.

At the same time, tirzepatide, while still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April.

"The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.

Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bari-


atric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower.

"Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. "However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike

Out of breath



SANJAY KOUJAL
New Delhi, 8 May

Respiratory drug sales rose 177 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFPM) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer.

According to Pharmarak, respiratory therapy sales rose to ₹1,632 crore in April from ₹1,386 crore Y-o-Y.

The growth was led by cough-and-cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months.

"Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram.

He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, NASA and the FBI.

The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files."

The Pentagon says additional documents will be released on a rolling basis.

Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known.

The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator.

The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Ceraterra Innosoch, among others.

The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

You read
Business Standard
to invest smarter.
Read Wirecutter
to spend smarter.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.34	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporates), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporates) and on the Company's website.

Place: Thrissur
Date: 08 May 2026

For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

Generic GLP-1 sales rise, but innovators retain mkt share

Over 25 versions of weight-loss drugs currently available in the market

SANJAY KOUJAL
New Delhi, 8 May

Innovator molecules of diabetes and weight loss drugs semaglutide and tirzepatide have been able to retain their market share despite rising competition from generics, as a class of doctors and patients show stickiness for the reference products.

More than 25 versions of semaglutide entered the market within days of the molecule's patent expiry on March 20, boosting sales of drugs based on the formulation.

Semaglutide sales rose about 51 per cent month-on-month (M-o-M) to ₹88 crore in April 2026, from ₹58 crore last month. Its contribution to the glucagon-like peptide-1 (GLP-1) market also increased to 40 per cent last month, from 33 per cent in March, according to data from market research firm Pharmarak. Of this, both innovator and generic semaglutide have risen in ₹44 crore each as sales revenue.

"However, the innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability," a Delhi-based endocrinologist told *Business Standard*.

At the same time, tirzepatide, while still dominating the market with 35 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to ₹121 crore in April 2026, from ₹114 crore in March. In terms of units sold, both semaglutide innovators and



Strength check

GLP-1 market in 2026 (Sales in ₹ crore)

Molecule	March	April	% chg
Tirzepatide	114	121	6.1
Semaglutide total*	58	88	51.7
Innovator molecules	46	44	-4.3
Generic	13	44	238.4
Dulaglutide	5	6	20.0
Liraglutide	3	2	-33.0

*Sum of innovator molecules and generics
Source: Pharmarak

generics have seen a rise, indicating sustained demand for both versions. Around 137,000 units of generic semaglutide were sold in April, a 242 per cent rise from the 40,000 units sold in March this year.

Innovator molecules such as Ozempic and Wegovy, however, also witnessed an increase of around 39 per cent from 23,000 units sold in March to 32,000 units in April.

"The volume impact of generics, along with strong unit growth indicates increased affordability along with aggressive promotion expanding the market," said Sheetal Sapale, vice president (commercial) at Pharmarak. She added that the steady growth of innovators also indicates stickiness of a class of doctors and patients to innovators.


Sukhvinder Singh Saggi, director for minimal access, gastrointestinal and bari-

atric surgery at Delhi's CK Birla Hospital said while many patients prefer generic semaglutide due to lower pricing, physicians believe that their efficacy and bio-availability may be comparatively lower.

"Generic formulations can sometimes involve more complex or larger molecules, which may affect how efficiently they work in the body. If the molecule does not effectively cross the blood-brain barrier, its action on the hypothalamus, the area where semaglutide helps regulate hunger and appetite, may not be as strong," he added.

Another doctor said innovator brands are generally considered more reliable in terms of efficacy. "However, when it comes to affordability, generic versions are definitely less expensive and therefore, more accessible to many patients," he added.

Respiratory drug sales up 18% as asthma cases spike



SANJAY KOUJAL
New Delhi, 8 May

Respiratory drug sales rose 177 per cent year-on-year (Y-o-Y) in April 2026, outpacing the overall Indian pharmaceutical market (IFPI) growth of 10.3 per cent, driven by seasonal flu and an unusual rise in asthma therapies despite summer.

According to Pharmarak respiratory therapy sales rose to ₹1,386 crore in April from ₹1,163 crore Y-o-Y.

The growth was led by cough-and-cold medicines and nasal preparations, which rose 13 per cent and 31 per cent, respectively, amid a seasonal flu spike, said Sheetal Sapale, vice-

president (commercial) at Pharmarak. Asthma and chronic obstructive pulmonary disease (COPD) drugs also posted a 22 per cent rise in April, even though demand for such therapies typically peaks in winter months.

"Although the use of such drugs increases during winter, orders have risen due to poor air quality, temperature fluctuations, dust exposure and high pollution levels," said Kuldeep Kumar Grover, associate director, pulmonology and critical care, GK Birla Hospital, Gurugram.

He added that even minor environmental changes can aggravate asthma symptoms, including wheezing, cough and breathlessness.



Pentagon releases UFO files

Experts have urged caution, warning that UAP videos are often misinterpreted, mischaracterised



(Left) Actual site photo with FBI lab rendered graphic overlay depicting corroborating eyewitness reports from September 2023 of an apparent ellipsoid bronze metallic object materialising out of a bright light in the sky; and US Indo-Pacific Command reported UAP that resembles a football-shaped body near Japan

ASSOCIATED PRESS
Washington, 8 May

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on "unidentified anomalous phenomena." Besides the Pentagon, the effort is led by the White House, the director of national intelligence, the Energy Department, Nasa and the FBI.

The Pentagon said on Friday in a post on X that while past administrations sought to discredit or dissuade the American people, President Donald Trump "is focused on providing maximum transparency to the public, who can ultimately make up their own minds

about the information contained in these files."

The Pentagon says additional documents will be released on a rolling basis.

Trump has been teasing the announcement since February. He had previously released records related to the assassinations of President John F. Kennedy, Sen Robert F. Kennedy, and Martin Luther King Jr that revealed little beyond what was already known.

The Pentagon has been working on declassifying documents related to UFOs for years, and Congress created an office in 2022 to declassify material. Its 2024 debut report revealed hundreds of new UAP incidents but found no evidence that the US government had

INDIA DEEP TECH ALLIANCE

Polsky Centre selects 20 startups for maiden cohort

AASHISH ARYAN
New Delhi, 8 May

The University of Chicago's Polsky Centre has selected 20 Indian startups for the inaugural cohort of the India Deep Tech Alliance's (IDTA) India Deep Tech Accelerator.

The accelerator programme, led by the Polsky Centre, aims to help the Indian Institute of Technology (IIT)-affiliated firms develop their research into scalable, market-ready products and firms.

Under the programme, startups such as Adapt, which has developed a unified AI middleware platform that routes queries across models with built-in cost optimisation, security and action layers, and Albatross, which has developed energy-efficient liquid-desiccant cooling systems that cut industrial air-conditioning costs and humidity by up to 50 per cent, have been selected. Other startups selected in the first cohort include Augie AI, BioSky Space Innovations, and Ceraterra Innosoch, among others.

The startups selected in the inaugural cohort will take part in a 10-week programme that began in April and will run until June. Under the programme, these selected startups will take part in workshops and get introduced to global customers, partners and investors.

You read
Business Standard
to invest smarter.
Read Wirecutter
to spend smarter.



Subscribe to Business Standard digital and get complimentary access to The New York Times.

Business Standard
The New York Times



Scan to know more

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnamm, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone					Consolidated				
	For the quarter ended		For the year ended			For the quarter ended		For the year ended		
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)
1 Total income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02	1,04,075.98	62,223.58	3,59,508.83	2,51,896.67
2 Net profit/(loss) for the period before tax before exceptional items	4,953.49	5,825.78	2,494.15	17,739.14	9,322.65	5,388.19	6,014.38	2,506.05	18,434.93	9,596.01
3 Net profit/(loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19	5,599.36	2,506.05	18,019.91	9,596.01
4 Net profit/(loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03	4,162.98	1,876.05	13,503.95	7,141.73
5 Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91	4,023.67	2,288.89	16,758.61	7,607.56
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-	-	-	52,759.73	37,721.43
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97	4.03	1.82	13.08	6.93
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95	4.03	1.82	13.05	6.93

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporate), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporate) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of THE BOARD OF DIRECTORS
T.S. Kalyanamm
Managing Director
DIN: 01021928

भारत की स्वदेशी नई हथियार प्रणाली 'तारा' का सफल परीक्षण

हेमंत कुमार रावत
पुणेकर, 8 मई

ऑपरेशन सिंदूर के टीक एक साल बाद भारत ने ऑडिशन में बंगाल की खाड़ी के तट पर टैटिकल एडवांस्ड रेंज ऑपरेशन (तारा) हथियार प्रणाली को सफल परीक्षण के साथ, अपनी स्वदेशी वायु क्षमता में एक और निगाहबंदी छलांग का इंतजार किया। रक्षा अधिकारियों ने आज इसकी जानकारी दी। ऑपरेशन सिंदूर ने देश को सैन्य प्रणाली में व्यापक बदलाव लाया था और दूर से सटीक हमला करने की क्षमता (स्टैंड-ऑफ़ क्रिसिजन वॉरफेयर) को दिशा में महत्वपूर्ण रखा दिखाई दी।



ऑडिशन में बंगाल की खाड़ी तट पर तारा का किया गया परीक्षण

कि तारा को हैदराबाद को रिसर्च सेंटर इमारत (आरसीआर) और रक्षा अनुसंधान एवं विकास संगठन (डीआरडीओ) को अन्य प्रयोगशालाओं द्वारा डिजाइन और विकसित किया गया है। यह तारा का पहला स्वदेशी मॉड्यूलर ग्लाइड हथियार है जो परंपरिक विना ग्लाइड वाले बॉम्ब को लंबी दूरी के सटीक मारक क्षमता वाले हथियारों में बदल सकता है। इस सफल परीक्षण ने भारत की स्वदेशी रूप से विकसित लॉन्चिंग अल्फाईक प्रभावी सटीक मारक क्षमता वाले हथियार विकसित करने की दिशा में महत्वपूर्ण कौशल कायम किया है। यह काम लागत वाली प्रणाली मौजूदा हवाई हथियारों को परिवर्तन प्रदान करता है जो सटीकता के साथ मारक क्षमता को बढ़ाता है। एक वैज्ञानिक ने कहा, 'तारा अत्याधुनिक, कम लागत वाली प्रणाली का उपयोग करने वाला पहला ग्लाइड हथियार है। यह वायु सेना को काफी उच्च सटीकता के साथ सामरिक लक्ष्यों को भेचने की क्षमता प्रदान करता है। साथ ही पायलटों और विमानों को दुश्मन के रडार-निर्देशित मिसाइल

तारा पहले ही विभिन्न परीक्षणों में प्रवेश कर चुका है, जिससे इसके जल्द ही परिचालन में शामिल होने की उम्मीद है। अब विकास-सह-उत्पादन भागीदारी और अन्य उपयोग के सहयोग से उत्पादन गतिविधियों पर काम चल रहा है। रक्षा अनुसंधान एवं विकास विभाग के सचिव और डीआरडीओ के चेयरमैन सीएच कोचर ने इस सफल परीक्षण से जुड़े वैज्ञानिकों, इंजीनियरों, भारतीय वायु सेना और अर्थोपिक भागीदारी को बधाई दी। रक्षा मंत्री राजनथ सिंह ने इस पहल को भारत की स्वदेशी रक्षा क्षमताओं में महत्वपूर्ण प्रगति बताया।

तारा क्या है और यह कैसे काम करता है ? तारा को एयर-लॉन्च, लंबी दूरी के हवा से जमीन पर मार करने वाले सटीक हथियार के तौर पर डिजाइन किया गया है, ताकि विना ग्लाइड वाले परंपरिक हथियारों की तुलना में ग्लाइड वाले हथियारों का उपयोग करने में सक्षम हो सके। तारा का लक्ष्य सटीकता के साथ मारक क्षमता को बढ़ाता है। इसका उपयोग करने में सक्षम होना है। इसका बड़े पैमाने पर उत्पादन किया जा सकता है।

एनआईए मामलों की सुनवाई में तेजी

भाविनी मिश्रा
नई दिल्ली, 8 मई

सर्वोच्च न्यायालय ने राष्ट्रीय अन्वेषण अधिकांश (एनआईए) अधिनियम के तहत गठित विशेष अदालतों में एनआईए मामलों की सुनवाई में तेजी लाने के उद्देश्य से शुक्रवार को कई दिशानिर्देश जारी किए। न्यायालय ने आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्तरों और न्यायिक व्यय को आवश्यकता पर जोर दिया। मुख्य न्यायाधीश जयमूर्ति सूर्य कोत और न्यायमूर्ति जयमलया बाघोचें को एनआईए दफ्तरों में नई निर्देश दिए कि उच्च न्यायालय के

अधिकार क्षेत्र में लॉन्च 10 से 15 मुकदमों के लिए कम से कम एक विशेष एनआईए अदालत स्थापित की जानी चाहिए। सुनान के साथ शुरू की गई एक कमेटी के चार चार किए गए। इसका उद्देश्य नैकानूनी गतिविधियों (रोकथाम) अधिनियम संहिता न्यायालय में आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्तरों और न्यायिक व्यय को आवश्यकता पर जोर दिया।



चाहिए। अगर लॉन्च मामलों की संख्या 25 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए। अगर लॉन्च मामलों की संख्या 25 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए। एनआईए के केंद्र सरकार और एनआईए से इन विशेष अदालतों की स्थापना और उनके सुचारु संचालन के लिए प्रस्ताव सुनवाई दफ्तरों

सुनिश्चित करने के लिए संबंधित उच्च न्यायालयों के साथ समन्वय करने को कहा है। 'हम संबंधित अधिकारियों से उच्च न्यायालयों के साथ परामर्श करने और विशेष अदालतों के कर्मचारियों के लिए पर्याप्त जगह उपलब्ध करने का अनुरोध करते हैं। वहां पठाया गया अधिकांश एनआईए मामलों की संख्या 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालेंगे। राष्ट्रीय अन्वेषण अधिकांश अधिनियम की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालेंगे। एनआईए के केंद्र सरकार और एनआईए से इन विशेष अदालतों की स्थापना और उनके सुचारु संचालन के लिए प्रस्ताव सुनवाई दफ्तरों

Progress ... Powered by innovation Proven by results

SENATOR LUXE CERA

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2026

(₹ In Lakhs)

Sr. No.	Particulars	Quarter Ended 31.03.2026 (Audited)	Year Ended 31.03.2026 (Audited)	Quarter Ended 31.03.2025 (Audited)
1	Total Income from Operations	64,381.58	2,05,011.98	5,777.96
2	Net Profit / (Loss) for the period (before Tax, Exceptional Items)	9,285.42	27,691.93	1,005.79
3	Exceptional Items	1,045.29	(780.68)	(950.43)
4	Net Profit / (Loss) for the period before Tax (after Exceptional Items)	10,350.71	26,911.25	1,086.76
5	Net Profit / (Loss) for the period after Tax (after Exceptional Items)	7,713.59	20,418.56	858.28
6	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	7,689.41	20,450.47	858.413
7	Equity Share Capital (Face value of ₹ 5/- each)	644.88	644.88	644.88
8	Other Equity (Excluding revaluation reserve) as shown in the Audited Balance Sheet of the previous year	146,588.97		
9	Earnings per equity share of ₹ 5/- each (EPS) for the quarter not annualised:			
	(1) Basic (₹)	59.96	158.31	66.36
	(2) Diluted (₹)	59.96	158.31	66.36

Notes
 1. The above is an Extract of the detailed format of Audited financial results for quarter and year ended on 31st March, 2026 filed with the Stock Exchanges under Regulation - 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited financial results for the quarter and year ended 31st March, 2026 are available on the website of the Stock Exchange, www.bseindia.com & the Company's website (www.cera-india.com).
 2. During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company had recognised a provision of ₹ 1,845.97 lakhs towards incremental past service cost for gratuity and leave liabilities, disclosed as an exceptional item. Pursuant to subsequent clarifications, professional advice and actuarial valuation, the liability as at March 31, 2026 has been reassessed at ₹ 780.68 lakhs. Accordingly, excess provision of ₹ 1,065.29 lakhs has been reversed during the March 2026 quarter under exceptional items. The net impact of the reassessment has been duly recognised in the statement of profit and loss.
 3. During the quarter ended March 2025, the Company entered into an amicable settlement with Ms. Mita Tilo LLP and exited the partnership. Consequently, the entire investment of ₹ 8,05,00,000 lakhs was written off (including ₹ 1,50,43,000 lakhs received during the March 2025 quarter, and disclosed as an exceptional item).
 4. Figures of the previous periods have been regrouped/ reclassified/ restated wherever necessary to conform to the current period presentation.
 5. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 08.05.2026.
 Date : 8th May, 2026
 Place : Ahmedabad

By Order of the Board of Directors
For, Cera Sanitaryware Limited
Anupam Gupta
 Executive Director (Technical)
 (DIN: 05230850)

Cera Sanitaryware Limited
 Registered Office & Works: 9, GIDC Industrial Estate, Kadi 382715, District Mehsana, Gujarat
 CIN: L269110G1998PLC034400 Tel: (02764) 242329, 243000. E-mail: kadi@cera-india.com Website: www.cera-india.com

'क्रूज' में सवार भारतीय संक्रमित नहीं'

हंटावायरस के संक्रमण पर स्वास्थ्य मंत्रालय रख रहा बारीकी से नजर

संकेत कौल
नई दिल्ली, 8 मई

हंटावायरस संक्रमण के मामलों की निगरानी के लिए स्वास्थ्य मंत्रालय सक्रिय हो गया है। इसने पहिलीयारी उपाय संकेती निर्देश जारी किए हैं। सूत्रों के अनुसार एचबीसी होटलिस क्रूज जहाज पर हंटावायरस संक्रमण के मामलों को पता चलने के बाद यह कठम उठाया गया है, क्योंकि जहाज पर इस खतरनाक वायरस का संक्रमण फैला गया है, उसमें दो भारतीय भी सवार हैं। मंत्रालय राष्ट्रीय रोग निगरान केंद्र, एकीकृत रोग निगरानी कार्यक्रम, विश्व स्वास्थ्य संगठन और अन्य अंतरराष्ट्रीय स्वास्थ्य अधिकारियों के साथ समन्वय में स्थिति पर बारीकी से नजर रख रहा है।



एचबीसी होटलिस क्रूज से संबंधित हंटावायरस संक्रमण के एक मरीज (दूसरी बाईं ओर) को शिफाले हवाई अड्डे पर उतार कर अस्पताल ले जाया गया

मौजूद तीन यात्रियों को मौत इस वायरस के संक्रमण से होने की बात कही गई है। एक चर्चस्प अधिकांश ने बताया कि अंतरराष्ट्रीय स्वास्थ्य नियामकों से मिली जानकारी से पता चला है कि दो भारतीय नागरिक भी इस जहाज पर सवार हैं। अधिकारी ने कहा, 'दोनों

यात्रि वर्तमान में अस्पताल में (स्पॉन्सिमुय) हैं और दोनों को अंतरराष्ट्रीय स्वास्थ्य प्रोटोकॉल के तहत निगरानी में रखा गया है। एहतियाती उपायों के मद्देनजर राष्ट्रीय रोग निगरान केंद्र के तहत आने वाले सांकेतिक स्वास्थ्य अपातकालीन संचालन केंद्र ने स्थिति का आकलन करने और तैयारियों को समीक्षा के लिए संबंधित विभागों और राज्यों के वीटस्प अधिकांशों के साथ उच्च स्तर की समीक्षा बैठक की है। अधिकारी ने कहा, 'केंद्रीय स्वास्थ्य मंत्रालय पूरी तरह से तैयार है। वरत इन्क्यूबेचओ तथा अन्य अंतरराष्ट्रीय एजेंसियों के साथ मिलकर इससे निपटने के लिए काम कर रहा है।' सूत्रों ने यह भी बताया कि भारतीय नागरिकों के स्वास्थ्य और सुरक्षा के लिए सभी उपाय किए जा रहे हैं। इन्क्यूबेचओ के अनुसार, जहाज पर सक्रिय हुआ वायरस हंटावायरस का एंडीज स्ट्रेन है, जिसके मानव से मानव में फैलने की क्षमता कम होती है। यह तभी प्रभावित करता है जब कोई बहुत लंबे समय तक इसके संपर्क में रहे।

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnkunam, Thrissur, Kerala - 680 002
 CIN: L36911KL2009PLC024641
 Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

₹ in Millions

Particulars	Standalone			Consolidated		
	For the quarter ended		For the year ended	For the quarter ended		For the year ended
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)	31 March 2026 (Audited)
1 Total Income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02
2 Net profit / (loss) for the period before tax before exceptional items	4,953.49	3,825.78	2,494.15	17,739.14	9,322.65	5,388.19
3 Net profit / (loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	5,599.36	5,388.19
4 Net profit / (loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03
5 Total comprehensive income for the period (comprising profit for the period (after tax) and other comprehensive income (after tax))	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,326.63
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95

For and on behalf of the BOARD OF DIRECTORS
T.S. Kalyanraman
 Managing Director
 DIN: 01021928

Place: Thrissur
 Date: 08 May 2026

भारत की स्वदेशी नई हथियार प्रणाली

‘तारा’ का सफल परीक्षण

हेमंत कुमार राउत
पुनरार, 8 मई

ऑपरेशन सिद्ध के ठीक एक साल बाद भारत ने ऑडिशा में बंगाल की खाड़ी के तट पर टैकिंगल एडवर्ड रेंज ऑपरेशन (तारा) हथियार प्रणाली को सफल परीक्षण के साथ, अपनी स्वदेशी वायु क्षमता में एक और निगाहबंदी छलांग का इतना किया। रक्षा अधिकारियों ने आज इसकी जानकारी दी। ऑपरेशन सिद्ध ने देश को सैन्य प्रणाली में व्यापक बदलाव लाया था और दूर से सटीक हमला करने की क्षमता (स्टैंड-ऑफ प्रिसिजन वारफेयर) को दिशा में महत्वपूर्ण रखा दिखाई दी।



ऑडिशा में बंगाल की खाड़ी तट पर तारा का किया गया परीक्षण

कि तारा को हैदराबाद को रिसर्च सेंटर इमारत (आरसीआर) और रक्षा अनुसंधान एवं विकास संगठन (डीआरडीओ) को अन्य प्रयोगशालाओं द्वारा डिजाइन और विकसित किया गया है। यह तारा का पहला स्वदेशी मॉड्यूलर ग्लाइड हथियार है जो परंपरिक विना ग्लाइड वाले बॉम्बों को लंबी दूरी के सटीक मारक क्षमता वाले हथियारों में बदल सकता है। इस सफल परीक्षण ने भारत की स्वदेशी रूप से विकसित लॉन्चिंग अल्फाईक प्रभावी सटीक मारक क्षमता वाले हथियार विकसित करने की दिशा में महत्वपूर्ण कौशल कायम किया है। यह काम लागत वाली प्रणाली मौजूदा हवाई हथियारों को परिवर्तन प्रदान करता है, जो सटीकता और मारक क्षमता को बढ़ाता है। एक वैज्ञानिक ने कहा, 'तारा अत्याधुनिक, कम लागत वाली प्रणाली का उपयोग करने वाला पहला ग्लाइड हथियार है। यह वायु सेना को काफी उच्च सटीकता के साथ सामरिक लक्ष्यों को भेदने की क्षमता प्रदान करता है। साथ ही पायलटों और विमानों को दुश्मन के रडार-निर्देशित मिसाइल

तारा पहले ही विभिन्न परीक्षणों में प्रवेश कर चुका है, जिससे इसके जल्द ही परिचालन में शामिल होने की उम्मीद है। अब विकास-सह-उत्पादन भागीदारों और अन्य उपयोग के सहयोग से उत्पादन गतिविधियों पर काम चल रहा है। रक्षा अनुसंधान एवं विकास विभाग के सचिव और डीआरडीओ के चेयरमैन सीएच कोचर ने इस सफल परीक्षण से जुड़े वैज्ञानिकों, इंजीनियरों, भारतीय वायु सेना और अधिकारियों को बधाई दी। रक्षा मंत्री राजनथ सिंह ने इस पहल को भारत की स्वदेशी रक्षा क्षमताओं में महत्वपूर्ण प्रगति बताया।

तारा क्या है और यह कैसे काम करता है ? तारा को एयर-लॉन्च, लंबी दूरी के हवा से जमीन पर मार करने वाले सटीक हथियार के तौर पर डिजाइन किया गया है, ताकि विना ग्लाइड वाले परंपरिक हथियारों की तुलना में ग्लाइड वाले हथियारों का उपयोग करने में सक्षम हो सके। तारा को रक्षा में अपने लक्ष्य को और बंदूक सटीकता है। इसके पीछे लगे चतुर्भुज सिस्टम की आधुनिक प्रणाली जटिल युद्धस्थिति में मदद करती है।

‘क्रूज में सवार भारतीय संक्रमित नहीं’

हटावायरस के संक्रमण पर स्वास्थ्य मंत्रालय रख रहा बारीकी से नजर

संकेत कौल
नई दिल्ली, 8 मई

हटावायरस संक्रमण के मामलों की निगरानी के लिए स्वास्थ्य मंत्रालय सक्रिय हो गया है। इसने एकियाती उपग्रह संकेतों निर्देश जारी किए हैं। सूत्रों के अनुसार एचवी बीडीएस क्रूज जहाज पर हटावायरस संक्रमण के मामलों को तलाश करने के बाद यह कठम उठाया गया है, क्योंकि जहाज पर इस खतरनाक वायरस का संक्रमण पाया गया है, उसमें दो भारतीय भी सवार हैं। मंत्रालय राष्ट्रीय रोग निरोधक केंद्र, एकीकृत रोग निगरानी कार्यक्रम, विश्व स्वास्थ्य संगठन और अन्य अंतरराष्ट्रीय स्वास्थ्य अधिकारियों के साथ समन्वय में स्थिति पर बारीकी से नजर रख रहा है।



एचवी बीडीएस क्रूज से स्थिति हटावायरस संक्रमण के एक मरीज (दूसरी बाईं ओर) को शिफाले हवाई अड्डे पर उतार कर अस्पताल ले जाया गया

मौजूद तीन यात्रियों को मौत इस वायरस के संक्रमण से होने की बात कही गई है। एक चर्चस्पंद अधिकारी ने बताया कि अंतरराष्ट्रीय स्वास्थ्य नियामकों से मिली जानकारी से पता चला है कि दो भारतीय नागरिक भी इस जहाज पर सवार हैं। अधिकारी ने कहा, 'दोनों

यात्रि वर्गमान में अतिमहत्वपूर्ण (सफाई) हैं और दोनों को अंतरराष्ट्रीय स्वास्थ्य प्रोटोकॉल के तहत निगरानी में रखा गया है। एकियाती उपग्रहों के मद्देनजर राष्ट्रीय रोग निरोधक केंद्र के तहत आने वाले सांकेतिक स्वास्थ्य अपाठकालीन संचालन केंद्र ने स्थिति का आकलन करने और तैयारियों को समीक्षा के लिए संबंधित विभागों और राज्यों के चर्चस्पंद अधिकारियों के साथ उच्च-स्तरीय समीक्षा बैठक की है। अधिकारी ने कहा, 'केंद्रीय स्वास्थ्य मंत्रालय पूरी तरह से तैयार है। चर्चस्पंद एचवी बीडीएस अंतरराष्ट्रीय एजेंसियों के साथ मिलकर इससे निपटने के लिए काम कर रहा है।' सूत्रों ने यह भी बताया कि भारतीय नागरिकों के स्वास्थ्य और सुरक्षा के लिए सभी उपाय किए जा रहे हैं। उल्लेख्य और अनुसर, जहाज पर सक्रिय हुआ वायरस हटावायरस का एंडीज स्ट्रेन है, जिसके मानव से मानव में फैलने की क्षमता कम होती है। यह सभी प्रमाणित करता है जब कोई बहुत लंबे समय तक इसके संपर्क में रहे।

एनआईए मामलों की सुनवाई में तेजी

भाविनी मिश्रा
नई दिल्ली, 8 मई

सर्वोच्च न्यायालय ने राष्ट्रीय अन्वेषण अधिकांश (एनआईए) अधिनियम के तहत गठित विशेष अदालतों में एनआईए की सुनवाई में तेजी लाने के उद्देश्य से शुक्रवार को कई दिशानिर्देश जारी किए। न्यायालय ने आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्तरों और न्यायिक व्यय को आवश्यकता पर जोर दिया। मुख्य न्यायाधीश जयमूर्ति सुर्य कोत और न्यायमूर्ति जयमलया बाघोत को अनुआई वाले पीठ ने निर्देश दिया कि उच्च न्यायालय के

अधिकार क्षेत्र में लॉन्च 10 से 15 मुकदमों के लिए कम से कम एक विशेष एनआईए अदालत स्थापित की जानी चाहिए। वे निर्देश इस साल फरवरी में स्वतंत्रता के साथ शुरू की गई एक कानून के तहत जारी किए गए। इसका उद्देश्य नैकानूनी गतिविधियों (रोकथाम) अधिनियम संहिता न्यायालय में आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्तरों और न्यायिक व्यय को आवश्यकता पर जोर दिया। अतिरिक्त अदालतों को स्थापना के लिए खास धांचे को स्पष्ट करके लू पीठ ने कहा कि लंबित मुकदमों को संख्या 1.5 से अधिक होने पर दो विशेष अदालतें स्थापित की जानी



चाहिए। अगर लंबित मामलों की संख्या 2.5 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए। अगर लंबित मामलों की संख्या 2.5 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए। अगर लंबित मामलों की संख्या 2.5 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए। अगर लंबित मामलों की संख्या 2.5 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए।

सुनिश्चित करने के लिए संबंधित उच्च न्यायालयों के साथ समन्वय करने को कहा है। पीठ ने कहा, 'हम संबंधित अधिकारियों से उच्च न्यायालयों के साथ परामर्श करने और विशेष अदालतों के कालकाज के लिए पर्याप्त जगह उपलब्ध करने का अनुरोध करते हैं। वहां पीठान्त अधिकारी इस अधिनियम की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालें।' राष्ट्रीय अन्वेषण अधिकांश अधिनियम की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालें। राष्ट्रीय अन्वेषण अधिकांश अधिनियम की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालें।

Progress ... Powered by innovation Proven by results

SENATOR LUXE CERA

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2026

Sr. No.	Particulars	Quarter Ended		
		31.03.2026 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	Total Income from Operations	64,381.58	2,05,011.98	5,777.96
2	Net Profit / (Loss) for the period (before Tax, Exceptional Items)	9,285.42	27,691.93	1,005.79
3	Exceptional Items	1,045.29	(780.68)	(950.43)
4	Net Profit / (Loss) for the period before Tax (after Exceptional Items)	10,350.71	26,911.25	1,086.76
5	Net Profit / (Loss) for the period after Tax (after Exceptional Items)	7,713.59	20,418.56	858.28
6	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	7,689.41	20,450.47	858.413
7	Equity Share Capital (Face value of ₹ 5/- each)	644.88	644.88	644.88
8	Other Equity (Excluding revaluation reserve) as shown in the Audited Balance Sheet of the previous year	146,588.97		
9	Earnings per equity share of ₹ 5/- each (EPS) for the quarter not annualised:			
	(1) Basic (₹)	59.96	158.31	66.36
	(2) Diluted (₹)	59.96	158.31	66.36

Notes
 1 The above is an Extract of the detailed format of Audited financial results for quarter and year ended on 31st March, 2026 filed with the Stock Exchanges under Regulation - 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited financial results for the quarter and year ended 31st March, 2026 are available on the website of the Stock Exchange (www.bseindia.com & www.nseindia.com) and the Company's website (www.cera-india.com).
 2 During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company had recognised a provision of ₹ 1,845.97 lakhs towards incremental past service cost for gratuity and leave liabilities, disclosed as an exceptional item. Pursuant to subsequent clarifications, professional advice and actuarial valuation, the liability as at March 31, 2026 has been reassessed at ₹ 780.68 lakhs. Accordingly, excess provision of ₹ 1,065.29 lakhs has been reversed during the March 2026 quarter under exceptional items. The net impact of the reassessment has been duly recognised in the statement of profit and loss.
 3 During the quarter ended March 2025, the Company entered into an amicable settlement with Ms. Mita Tilo LLP and exited the partnership. Consequently, the entire investment of ₹ 8,06,00,000 lakhs was written off (including ₹ 1,50,43,000 lakhs recorded during the March 2025 quarter, and disclosed as an exceptional item).
 4 Figures of the previous periods have been regrouped/ reclassified/ restated wherever necessary to conform to the current period presentation.
 5 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 08.05.2026.
 Date : 8th May, 2026
 Place : Ahmedabad

By Order of the Board of Directors
For, Cera Sanitaryware Limited

Anupam Gupta
 Executive Director (Technical)
 (DIN: 05230850)

Cera Sanitaryware Limited
 Registered Office & Works: 9, GIDC Industrial Estate, Kadi 382715, District Mehsana, Gujarat
 CIN: L26910GJ1999PLC034400 Tel: (027861) 242329, 243000. E-mail: kadi@cera-india.com Website: www.cera-india.com



KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnkunam, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone			Consolidated		
	For the quarter ended		For the year ended	For the quarter ended		For the year ended
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 March 2025 (Unaudited)	31 March 2025 (Audited)
1 Total Income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02
2 Net profit / (loss) for the period before tax before exceptional items	4,953.49	3,825.78	2,494.15	17,739.14	9,322.65	5,388.19
3 Net profit / (loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	5,599.36	5,388.19
4 Net profit / (loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03
5 Total comprehensive income for the period (comprising profit for the period (after tax) and other comprehensive income (after tax))	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,326.63
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95

Note:
 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporate), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporate) and on the Company's website.



Place: Thrissur
 Date: 08 May 2026

For and on behalf of the BOARD OF DIRECTORS
T.S. Kalyanraman
 Managing Director
 DIN: 01021928

भारत की स्वदेशी नई हथियार प्रणाली

‘तारा’ का सफल परीक्षण

हेमंत कुमार रावत
पुणेकर, 8 मई

ऑपरेशन सिंदूर के टीक एक साल बाद भारत ने ओडिशा में बंगाल की खाड़ी के तट पर टैटिकल एडवांस्ड रेंज ऑपरेशन (तारा) हथियार प्रणाली को सफल परीक्षण के साथ, अपनी स्वदेशी वायु क्षमता में एक और निगमिक छलांग का इतना किया। रक्षा अधिकारियों ने आज इसकी जानकारी दी। ऑपरेशन सिंदूर ने देश को सैन्य प्रणाली में व्यापक बदलाव लाया था और दूर से सटीक हमला करने की क्षमता (स्टैंड-ऑफ प्रिसिजन वारफेयर) को दिशा में महत्वपूर्ण रखा दिखाई दी।



ओडिशा में बंगाल की खाड़ी तट पर तारा का किया गया परीक्षण

कि तारा को हैदराबाद को रिसर्च सेंटर इमारत (आरसीआर) और रक्षा अनुसंधान एवं विकास संगठन (डीआरडीओ) को अन्य प्रयोगशालाओं द्वारा डिजाइन और विकसित किया गया है। यह तारा का पहला स्वदेशी मॉड्यूलर ग्लाइड हथियार है जो परंपरिक विना ग्लाइड वाले बॉम्ब को लंबी दूरी के सटीक मारक क्षमता वाले हथियारों में बदल सकता है। इस सफल परीक्षण ने भारत की स्वदेशी रूप से विकसित लॉकम अत्याधिक प्रभावी सटीक मारक क्षमता वाले हथियार विकसित करने की दिशा में महत्वपूर्ण कौशल कायम किया है। यह काम लागत वाली प्रणाली मौजूदा हवाई हथियारों को परिवर्तन प्रदान करता है, जो सटीकता और मारक क्षमता को बढ़ाता है। एक वैज्ञानिक ने कहा, 'तारा अत्याधुनिक, कम लागत वाली प्रणाली का उपयोग करने वाला पहला ग्लाइड हथियार है। यह वायु सेना को काफी उच्च सटीकता के साथ सामूहिक लक्ष्यों को भेजने की क्षमता प्रदान करता है। साथ ही पायलटों और विमानों को दुश्मन के रडार-निर्देशित मिसाइल

तारा पहले ही विभिन्न परीक्षणों में प्रवेश कर चुका है, जिससे इसके जल्द ही परिचालन में शामिल होने की उम्मीद है। अब विकास-सह-उत्पादन भागीदारी और अन्य उद्योगों के सहयोग से उत्पादन गतिविधियों पर काम चल रहा है। रक्षा अनुसंधान एवं विकास विभाग के सचिव और डीआरडीओ के चेयरमैन सीएच कोचर ने इस सफल परीक्षण से जुड़े वैज्ञानिकों, इंजीनियरों, भारतीय वायु सेना और औद्योगिक भागीदारों को बधाई दी। रक्षा मंत्री राजन सिंह ने इस पहली रक्षा शक्ति में महत्वपूर्ण प्रगति बताया।

तारा क्या है और यह कैसे काम करता है ? तारा को एयर-लॉन्च, लंबी दूरी के हवा से जमीन पर मार करने वाले सटीक हथियार के तौर पर डिजाइन किया गया है, ताकि विना ग्लाइड वाले परंपरिक हथियारों की तुलना में ग्लाइड वाले हथियारों में बढ़ती क्षमता को रक्षा में आने लक्ष्य को और बुरा कर सकना हो। इसके पीछे लगे पंख इस सिस्टम को आखिरी चरण में जटिल युद्धाभ्यास में मदद करते हैं।

सूत्रों ने बताया कि यह हथियार कई कार्ट्रिज ग्रेनेड में उपलब्ध होगा, जिसमें तारा-250 लगभग 308 किलोग्राम के वजन के साथ जबकि तारा-450/500 का वजन लगभग 546 किलोग्राम होगा। मॉड्यूलर ग्लाइड और ग्लाइड फिट का वजन लगभग 98 किलोग्राम है, जिससे प्रमुख संरचनात्मक संशोधनों के बिना मौजूदा बम इन्वेंटरी के साथ एकीकरण संभव हो जाता है।

एनआईए मामलों की सुनवाई में तेजी

भाविनी मिश्रा
नई दिल्ली, 8 मई

सर्वोच्च न्यायालय ने राष्ट्रीय अन्वेषण अधिकांश (एनआईए) अधिनियम के तहत गठित विशेष अदालतों में फूट-दूरी की सुनवाई में तेजी लाने के उद्देश्य से शुक्रवार को कई दिशानिर्देश जारी किए। न्यायालय ने आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्ते और न्यायिक व्यय को आवश्यकता पर जोर दिया। मुख्य न्यायाधीश जयमूर्ति सूर्य कोट और न्यायमूर्ति जयमलया बाघचो के अग्र-आई वाले पीठ ने निर्देश दिया कि उच्च न्यायालय के

अधिकार क्षेत्र में लॉज 10 से 15 मुकदमों के लिए कम से कम एक विशेष एनआईए अदालत स्थापित की जानी चाहिए।

यदि ऐसा इस साल फरवरी में स्वतंत्रता के साथ शुरू की गई एक कानून के तहत 'बॉल फ्लोर' किए गए। इसका उद्देश्य नैकानूनी गतिविधियों (रोकथाम) अधिनियम संहिता न्यायालय में आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्ते और न्यायिक व्यय को आवश्यकता पर जोर दिया।

अतिरिक्त अदालतों को स्थापना के लिए खास धांचे को स्पष्ट कर ले। पीठ ने कहा कि लंबित मुकदमों को संख्या 1.5 से अधिक होने पर दो विशेष अदालतें स्थापित की जानी



चाहिए। अगर लॉज मामले को संख्या 2.5 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए।

न्यायालय ने केंद्र सरकार और एनआईए से इन विशेष अदालतों की स्थापना और उनके सूचारु संचालन के लिए प्रस्ताव सुनवाई दफ्ते

सुनिश्चित करने के लिए संबंधित उच्च न्यायालयों के साथ समन्वय करने को कहा है।

पीठ ने कहा, 'हम संबंधित अधिकारियों से उच्च न्यायालयों के साथ परामर्श करने और विशेष अदालतों के कालकाज के लिए पर्याप्त जगह उपलब्ध करने का अनुरोध करते हैं। वहां पीठान्वित अधिकारी इस अधिनियम की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालें।'

राष्ट्रीय अन्वेषण अधिकांश अधिनियम की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालें।

Progress ... Powered by innovation Proven by results

SENATOR LUXE CERA

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2026

Sr. No.	Particulars	Quarter Ended		
		31.03.2026 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	Total Income from Operations	64,381.58	2,050.98	5,777.96
2	Net Profit / (Loss) for the period (before Tax, Exceptional Items)	9,285.42	2,691.93	1,005.79
3	Exceptional Items	1,045.29	(780.68)	(950.43)
4	Net Profit / (Loss) for the period before Tax (after Exceptional Items)	10,350.71	2,691.25	1,086.76
5	Net Profit / (Loss) for the period after Tax (after Exceptional Items)	7,713.59	2,048.56	858.28
6	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	7,689.41	2,045.07	858.413
7	Equity Share Capital (Face value of ₹ 5/- each)	644.88	644.88	644.88
8	Other Equity (Excluding revaluation reserve) as shown in the Audited Balance Sheet of the previous year	146,588.97		
9	Earnings per equity share of ₹ 5/- each (EPS) for the quarter not annualised:			
	(1) Basic (₹)	59.96	158.31	66.36
	(2) Diluted (₹)	59.96	158.31	66.36

Notes

- The above is an Extract of the detailed format of Audited financial results for quarter and year ended on 31st March, 2026 filed with the Stock Exchanges under Regulation - 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited financial results for the quarter and year ended 31st March, 2026 are available on the website of the Stock Exchange (www.bseindia.com & www.nseindia.com) and the Company's website (www.cera-india.com).
- During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company had recognised a provision of ₹ 1,845.97 lakhs towards incremental past service cost for gratuity and leave liabilities, disclosed as an exceptional item. Pursuant to subsequent clarifications, professional advice and actuarial valuation, the liability as at March 31, 2026 has been reassessed at ₹ 780.68 lakhs. Accordingly, excess provision of ₹ 1,065.29 lakhs has been reversed during the March 2026 quarter under exceptional items. The net impact of the reassessment has been duly recognised in the statement of profit and loss.
- During the quarter ended March 2025, the Company entered into an amicable settlement with Ms. Mita Tilo LLP and exited the partnership. Consequently, the entire investment of ₹ 8,06,00,000 lakhs was written off (including ₹ 1,50,43,000 lakhs received during the March 2025 quarter, and disclosed as an exceptional item).
- Figures of the previous periods have been regrouped/ reclassified/ restated wherever necessary to conform to the current period presentation.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 08.05.2026.

Date : 8th May, 2026
Place : Ahmedabad

**By Order of the Board of Directors
For, Cera Sanitaryware Limited**

Anupam Gupta
Executive Director (Technical)
(DIN: 05230850)

‘क्रूज में सवार भारतीय संक्रमित नहीं’

हंटावायरस के संक्रमण पर स्वास्थ्य मंत्रालय रख रहा बारीकी से नजर

संकेत कौल
नई दिल्ली, 8 मई

हंटावायरस संक्रमण के मामलों की निगरानी के लिए स्वास्थ्य मंत्रालय सक्रिय हो गया है। इसने पहिलीयारी उपाय संकेती निर्देश जारी किए हैं। सूत्रों के अनुसार एचवी बीडीएस क्रूज जहाज पर हंटावायरस संक्रमण के मामलों को तलाश करने के बाद यह कदम उठाया गया है, क्योंकि जहाज पर इस खतरनाक वायरस का संक्रमण फैला गया है, उसमें दो भारतीय भी सवार हैं। मंत्रालय राष्ट्रीय रोग निरोधक केंद्र, एकीकृत रोग निगरानी कार्यक्रम, विश्व स्वास्थ्य संगठन और अन्य अंतरराष्ट्रीय स्वास्थ्य अधिकारियों के साथ समन्वय में स्थिति पर बारीकी से नजर रख रहा है।



एचवी बीडीएस क्रूज से स्थिति हंटावायरस संक्रमण के एक मरीज (दूसरी बाईं ओर) को शिफाले हवाई अड्डे पर उतार कर अस्पताल ले जाया गया

व्यक्ति वर्तमान में अस्पताल में (सफाई) हैं और दोनों को अंतरराष्ट्रीय स्वास्थ्य प्रोटोकॉल के तहत निगरानी में रखा गया है।

एहतियाती उपायों के मद्देनजर राष्ट्रीय रोग निरोधक केंद्र के तहत आने वाले सांकेतिक स्वास्थ्य अपातकालीन संचालन केंद्र ने स्थिति का आकलन करने और तैयारियों को समीक्षा के लिए संबंधित विभागों और राज्यों के वरिष्ठ अधिकारियों के साथ उच्च-स्तरीय समीक्षा बैठक की है। अधिकारी ने कहा, 'केंद्रीय स्वास्थ्य मंत्रालय पूरी तरह से तैयार है। वरिष्ठ अधिकारियों ने बताया कि अंतरराष्ट्रीय स्वास्थ्य नियामकों से मिली जानकारी से पता चला है कि दो भारतीय नागरिक भी इस जहाज पर सवार हैं। अधिकारी ने कहा, 'दोनों

नौदल के इस क्रूज जहाज एमबी ग्रींडरस पर हंटावायरस संक्रमण के कुल आठ संभावित मामलों का पता चला था। डब्ल्यूएचओ को इस महानि के पहले सतर्कता में इस बारे में सूचना मिली थी। पंच मामलों की पुष्टि प्रयोगशाला में हुई थी। लंबे यात्रा पर निकले इस जहाज पर

मौजूद तीन यात्रियों को मौत इस वायरस के संक्रमण से होने की बात कही गई है। एक वरिष्ठ अधिकारी ने बताया कि अंतरराष्ट्रीय स्वास्थ्य नियामकों से मिली जानकारी से पता चला है कि दो भारतीय नागरिक भी इस जहाज पर सवार हैं। अधिकारी ने कहा, 'दोनों

व्यक्ति वर्तमान में अस्पताल में (सफाई) हैं और दोनों को अंतरराष्ट्रीय स्वास्थ्य प्रोटोकॉल के तहत निगरानी में रखा गया है।

एहतियाती उपायों के मद्देनजर राष्ट्रीय रोग निरोधक केंद्र के तहत आने वाले सांकेतिक स्वास्थ्य अपातकालीन संचालन केंद्र ने स्थिति का आकलन करने और तैयारियों को समीक्षा के लिए संबंधित विभागों और राज्यों के वरिष्ठ अधिकारियों के साथ उच्च-स्तरीय समीक्षा बैठक की है। अधिकारी ने कहा, 'केंद्रीय स्वास्थ्य मंत्रालय पूरी तरह से तैयार है। वरिष्ठ अधिकारियों ने बताया कि अंतरराष्ट्रीय स्वास्थ्य नियामकों से मिली जानकारी से पता चला है कि दो भारतीय नागरिक भी इस जहाज पर सवार हैं। अधिकारी ने कहा, 'दोनों

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnkunam, Thrissur, Kerala - 680 002

CIN: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Particulars	Standalone			Consolidated		
	For the quarter ended		For the year ended	For the quarter ended		For the year ended
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)
1 Total Income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02
2 Net profit / (loss) for the period before tax before exceptional items	4,953.49	3,825.78	2,494.15	17,739.14	9,322.65	5,388.19
3 Net profit / (loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19
4 Net profit / (loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03
5 Total comprehensive income for the period (comprising profit for the period (after tax) and other comprehensive income (after tax))	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,326.63
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95

Note: 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporate), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporate) and on the Company's website.



Place: Thrissur
Date: 08 May 2026

For and on behalf of the BOARD OF DIRECTORS
T.S. Kalyanraman
Managing Director
DIN: 01021928

भारत की स्वदेशी नई हथियार प्रणाली

‘तारा’ का सफल परीक्षण

हेमंत कुमार रावत पुणेकर, 8 मई

ऑपरेशन सिद्ध के ठीक एक साल बाद भारत ने ओडिशा में बंगाल की खाड़ी के तट पर टैंकिकल एडवेंस रेंज ऑपरेशन (तारा) हथियार प्रणाली को सफल परीक्षण के साथ, अपनी स्वदेशी वायु क्षमता में एक और निगमिक छलांग का इतना किया। रक्षा अधिकारियों ने आज इसकी जानकारी दी। ऑपरेशन सिद्ध ने देश को सैन्य प्रणाली में व्यापक बदलाव लाया था और दूर से सटीक हमला करने की क्षमता (स्टैंड-ऑफ़ प्रिसिजन बॉम्बर) को दिशा में महत्वपूर्ण रक्षा दिखाई दी।



ओडिशा में बंगाल की खाड़ी तट पर तारा का किया गया परीक्षण

कि तारा को हैदराबाद को रिसर्च सेंटर इमरत (आरसीआर) और रक्षा अनुसंधान एवं विकास संगठन (डीआरडीओ) को अन्य प्रयोगशालाओं द्वारा डिजाइन और विकसित किया गया है। यह तारा का पहला स्वदेशी मॉड्यूलर ग्लाइड हथियार है जो परंपरिक विना ग्लाइड वाले बॉम्ब के लंबी दूरी के सटीक मार्ग क्षमता वाले हथियारों में बदल सकता है। इस सफल परीक्षण ने भारत की स्वदेशी रूप से विकसित लॉन्च अल्थाइक प्रभावी सटीक मार्ग क्षमता वाले हथियार विकसित करने की दिशा में महत्वपूर्ण कौशल कायम किया है। यह काम लागत वाली प्रणाली मौजूदा हवाई हथियारों को परिवर्तन प्रदान करता है और मार्ग क्षमता को बढ़ाता है। एक वैज्ञानिक ने कहा, 'तारा अत्याधुनिक, कम लागत वाली प्रणाली का उपयोग करने वाला पहला ग्लाइड हथियार है। यह वायु सेना को काफी उच्च सटीकता के साथ सामूहिक लक्ष्यों को भेजने की क्षमता प्रदान करता है। साथ ही पायलटों और विमानों को दुश्मन के रडार-निर्देशित मिसाइल

तारा पहले ही विभिन्न परीक्षणों में प्रवेश कर चुका है, जिससे इसके जल्द ही परिचालन में शामिल होने की उम्मीद है। अब विकास-सह-उत्पादन भागीदारों और अन्य उपयोग के सहयोग से उत्पादन गतिविधियों पर काम चल रहा है। रक्षा अनुसंधान एवं विकास विभाग के सचिव और डीआरडीओ के चेयरमैन सीएच कोचर ने इस सफल परीक्षण से जुड़े वैज्ञानिकों, इंजीनियरों, भारतीय वायु सेना और औद्योगिक भागीदारों को बधाई दी। रक्षा मंत्री राजन सिंह ने इस पहल को भारत की स्वदेशी रक्षा क्षमताओं में महत्वपूर्ण प्रगति बताया।

तारा क्या है और यह कैसे काम करता है? तारा को एयर-लॉन्च, लंबी दूरी के हवा से जमीन पर मार करने वाले सटीक हथियार के तौर पर डिजाइन किया गया है, ताकि विना ग्लाइड वाले परंपरिक हथियारों की तुलना में ग्लाइड वाले हथियारों का उपयोग करने में सक्षम हो सके। यह 6.50 किलोमीटर प्रति घंटा से ज्यादा की रफ्तार से अपने लक्ष्य को और बंद सकता है। इसके पीछे लगे चतुर्भुज सिस्टम की आखिरी चरण में जेट इंजन प्रणाली में मदद करती है।

एनआईए मामलों की सुनवाई में तेजी

भाविनी मिश्रा नई दिल्ली, 8 मई

सर्वोच्च न्यायालय ने राष्ट्रीय अन्वेषण अधिकांश (एनआईए) अधिनियम के तहत गठित विशेष अदालतों में एनआईए की सुनवाई में तेजी लाने के उद्देश्य से शुक्रवार को कई दिशानिर्देश जारी किए। न्यायालय ने आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्तरों और न्यायिक व्यय को आवश्यक न्याय प्रदान करने को अनुरोध किया।

अधिकार क्षेत्र में लॉन्च 10 से 15 मुकदमों के लिए कम से कम एक विशेष एनआईए अदालत स्थापित की जानी चाहिए। सुनान के साथ शुरू की गई एक कमेटी के चार चरण किए गए। इसका उद्देश्य नैकानूनी गतिविधियों (रोकथाम) अधिनियम संहिता न्यायालय में आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्तरों और न्यायिक व्यय को आवश्यक न्याय प्रदान करने को अनुरोध किया।



चौहान। अगर लॉन्च मामलों की संख्या 25 के पार पहुंच गई है तो तीन ऐसे अदालत स्थापित की जानी चाहिए। अगर लॉन्च मामलों की संख्या 25 के पार पहुंच गई है तो तीन ऐसे अदालत स्थापित की जानी चाहिए। अगर लॉन्च मामलों की संख्या 25 के पार पहुंच गई है तो तीन ऐसे अदालत स्थापित की जानी चाहिए।

सुनिश्चित करने के लिए संबंधित उच्च न्यायालयों के साथ समन्वय करने को कहा है। 'हम संबंधित अधिकारियों से उच्च न्यायालयों के साथ परामर्श करने और विशेष अदालतों के कर्मचारियों के लिए पर्याप्त जगह उपलब्ध करने का अनुरोध करते हैं। वहां पठाया गया अधिकारी इन अधिनियम की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालें।' राष्ट्रीय अन्वेषण अधिकांश अधिनियम की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालें।

Advertisement for CERA featuring images of kitchenware and the text 'Progress ... Powered by innovation Proven by results'. It also lists product names like SENATOR, LUXE, and CERA.

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2026

Table with 5 columns: Sr. No., Particulars, Quarter Ended 31.03.2026 (Audited), Year Ended 31.03.2026 (Audited), Quarter Ended 31.03.2025 (Audited). It lists various financial metrics like Total Income, Net Profit, and Equity Share Capital.

Notes: 1. The above is an Extract of the detailed format of Audited financial results for quarter and year ended on 31st March, 2026 filed with the Stock Exchanges under Regulation - 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited financial results for the quarter and year ended 31st March, 2026 are available on the website of the Stock Exchange, www.bseindia.com & www.nseindia.com and the Company's website (www.cera-india.com).

‘क्रूज में सवार भारतीय संक्रमित नहीं’

हंटावायरस के संक्रमण पर स्वास्थ्य मंत्रालय रख रहा बारीकी से नजर

संकेत कौल नई दिल्ली, 8 मई

हंटावायरस संक्रमण के मामलों की निगरानी के लिए स्वास्थ्य मंत्रालय सक्रिय हो गया है। इसने पहिल्यांती उपाय संकेती निर्देश जारी किए हैं। सूत्रों के अनुसार एचवी बीडीएस क्रूज जहाज पर हंटावायरस संक्रमण के मामलों को तलाश करने के बाद यह कठम उठाया गया है, क्योंकि जहाज पर इस खतरनाक वायरस का संक्रमण फैला गया है, उसमें दो भारतीय भी सवार हैं। मंत्रालय राष्ट्रीय रोग निरोधक केंद्र, एकीकृत रोग निगरानी कार्यक्रम, विश्व स्वास्थ्य संगठन और अन्य अंतरराष्ट्रीय स्वास्थ्य अधिकारियों के साथ समन्वय में स्थिति पर बारीकी से नजर रख रहा है।



एमवी हेलिक्स क्रूज से स्थिति हंटावायरस संक्रमण के एक मरीज (दूसरी बाईं ओर) को शिफाले हवाई अड्डे पर उतार कर अस्पताल ले जाया गया

व्यक्ति वर्तमान में अस्पताल में (सफाई) हैं और दोनों को अंतरराष्ट्रीय स्वास्थ्य प्रोटोकॉल के तहत निगरानी में रखा गया है। एहतियाती उपायों के मद्देनजर राष्ट्रीय रोग निरोधक केंद्र के तहत आने वाले सांकेतिक स्वास्थ्य अपाठकालीन संचालन केंद्र ने स्थिति का आकलन करने और तैयारियों को समीक्षा के लिए संबंधित विभागों और राज्यों के वरिष्ठ अधिकारियों के साथ उच्च-स्तरीय समीक्षा बैठक की है। अधिकारी ने कहा, 'केंद्रीय स्वास्थ्य मंत्रालय पूरी तरह से तैयार है। वरिष्ठ अधिकारी उपायों के साथ अंतरराष्ट्रीय एजेंसियों के साथ मिलकर इससे निपटने के लिए काम कर रहा है।' सूत्रों ने यह भी बताया कि भारतीय नागरिकों के स्वास्थ्य और सुरक्षा के लिए सभी उपाय किए जा रहे हैं। उल्लेख्य ओं के अनुसार, जहाज पर सक्रिय हुआ वायरस हंटावायरस का एंडीज स्ट्रेन है, जिसके मानव से मानव में फैलने की क्षमता कम होती है। यह सभी प्रभावित करता है जब कोई बहुत लंबे समय तक इसके संपर्क में रहे।

नौदल के इस क्रूज जहाज एमवी गौडरस पर हंटावायरस संक्रमण के कुल आठ संभावित मामलों का पता चला था। उल्लेख्य ओं को इस कहाने के पहले सप्ताह में इस बारे में सूचना मिली थी। पंच मामलों की पुष्टि प्रयोगशाला में हुई थी। लंबे यात्रा पर निकले इस जहाज पर

मौजूद तीन यात्रियों को मौत इस वायरस से संक्रमण से होने की बात कही गई है। एक वरिष्ठ अधिकारी ने बताया कि अंतरराष्ट्रीय स्वास्थ्य नियामकों से मिली जानकारी से पता चला है कि दो भारतीय नागरिक भी इस जहाज पर सवार हैं। अधिकारी ने कहा, 'दोनों

KALYAN JEWELLERS INDIA LIMITED

Registered Office: TC-32/204/2, Sitaram Mill Road, Punnunnam, Thrissur, Kerala - 680 002

ON: L36911KL2009PLC024641

Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Table with 10 columns: Particulars, Standalone (For the quarter ended, For the year ended), Consolidated (For the quarter ended, For the year ended). It lists financial metrics like Total Income, Net Profit, and Equity Share Capital.

Note: 1. The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Limited website (URL: www.bseindia.com/corporate), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporate) and on the Company's website.



Place: Thrissur Date: 08 May 2026

For and on behalf of the BOARD OF DIRECTORS T.S. Kalyanraman Managing Director DIN: 01021928

भारत की स्वदेशी नई हथियार प्रणाली

‘तारा’ का सफल परीक्षण

हेमंत कुमार रावत
पुणेकर, 8 मई

ऑपरेशन सिंदूर के टोक एक साल बाद भारत ने ऑडिशन में बंगाल की खाड़ी के तट पर टेस्टिंग एडवर्ड रेंज ऑपरेशन (तारा) हथियार प्रणाली को सफल परीक्षण के साथ, अपनी स्वदेशी वायु क्षमता में एक और निगाहबंदी छलांग का इंतजार किया। रक्षा अधिकारियों ने आज इसकी जानकारी दी। ऑपरेशन सिंदूर ने देश को सैन्य प्रणाली में व्यापक बदलाव लाया था और दूर से सटीक हमला करने की क्षमता (स्टैंड-ऑफ़ प्रिसिजन वारफेयर) को दिशा में महत्वपूर्ण रखा दिखाई देती है।



ऑडिशन में बंगाल की खाड़ी तट पर तारा का किया गया परीक्षण

कि तारा को हैदराबाद को रिसर्च सेंटर इमारत (आरसीआर) और रक्षा अनुसंधान एवं विकास संगठन (डीआरडीओ) को अन्य प्रयोगशालाओं द्वारा डिजाइन और विकसित किया गया है। यह तारा का पहला स्वदेशी मॉड्यूलर ग्लाइड हथियार है जो परंपरिक विमान ग्राहक वाहन बॉम्बेडर को लंबी दूरी के सटीक मारक क्षमता वाले हथियारों में बदल सकता है। इस सफल परीक्षण ने भारत की स्वदेशी रूप से विकसित लॉन्चिंग अल्बर्ट प्रणाली सटीक मारक क्षमता वाले हथियार विकसित करने की दिशा में महत्वपूर्ण कौशल कायम किया है। यह काम लागत वाली प्रणाली मौजूदा हवाई हथियारों को परिवर्तन प्रदान करता है, जो सटीकता और मारक क्षमता को बढ़ाती है। एक वैज्ञानिक ने कहा, 'तारा अत्याधुनिक, कम लागत वाली प्रणाली का उपयोग करने वाला पहला ग्लाइड हथियार है। यह वायु सेना को काफी उच्च सटीकता के साथ सामरिक लक्ष्यों को भेजने की क्षमता प्रदान करता है। साथ ही पायलटों और विमानों को दुश्मन के रडार-निर्देशित मिसाइल

प्रणालियों के संपर्क में आने के खतरे को भी कम करता है।' उन्होंने कहा कि इलेक्ट्रॉनिक्स-ऑप्टिकल और इमर्जिंग इन्फ्रारेड टर्मिनल माइनिंग का समावेश विशेष रूप से महत्वपूर्ण है क्योंकि यह संभव है कि काम कर सकता है जब सेंटरलैट्ट नेविगेशन को खराब या जाम किया जा सकता है। रक्षा विशेषज्ञों के अनुसार ऑपरेशन सिंदूर को पहली वर्षांतर पर यह वास्तव परीक्षण हाल के वर्षों में सबसे लेकर अंतरिक्ष क्षमता विकसित करने के भारत के प्रयास को मजबूत करता है।

भारतीय वायु सेना के पूर्व अधिकारी एन के सामल ने कहा, 'आधुनिक युद्धक्षेत्रों में यह क्षमता जरूरी होती है कि दुश्मन के हमले के दायरे से बाहर रहते हुए भी उच्च बुनियादी ढांचे, लॉजिस्टिक केंद्रों, रडार स्टेशनों, कमांड सेंटर्स और अलग-अलग सैन्य दुकानियों पर हमला किया जा सके। तारा भारतीय वायु सेना की स्वदेशी, कम लागत वाली 'स्टैंड-ऑफ़ स्ट्राइक' विकल्प के रूप में एक नया चरण प्रदान करता है। इसका बड़े पैमाने पर उत्पादन किया जा सकता है।

तारा पहले ही विभिन्न परीक्षणों में प्रवेश कर चुका है, जिसमें इसके जल्द ही परिवर्तन में शामिल होने की उम्मीद है। अब विकास-सह-उत्पादन भागीदारी और अन्य उपयोग के सहयोग से उत्पादन गतिविधियों पर काम चल रहा है। रक्षा अनुसंधान एवं विकास विभाग के सचिव और डीआरडीओ के चेयरमैन सीवी कोयतार ने इस सफल परीक्षण से जुड़े वैज्ञानिकों, इंजीनियरों, भारतीय वायु सेना और आर्थोपेडिक भागीदारी को बधाई दी। रक्षा मंत्री राजनथ सिंह ने इस पहल को भारत की स्वदेशी रक्षा क्षमताओं में महत्वपूर्ण प्रगति बताया।

तारा क्या है और यह कैसे काम करता है ? तारा को एयर-लॉन्च, लंबी दूरी के हवा से जमीन पर मार करने वाले सटीक हथियार के तौर पर डिजाइन किया गया है, ताकि विमान ग्राहक वाले परंपरिक हथियारों की तुलना में ग्लाइड वाले हथियारों का उपयोग करने में सक्षम बनाया जा सके। यह 6.50 किलोमीटर प्रति घंटा से ज्यादा की रफ्तार से आने लक्ष्य को और बंदूक सटीकता है। इसके पीछे लगे पंच ड्रैग सिस्टम की आखिरी चरण में जेट इंजन प्रणाली में मदद करती है।

सूत्रों ने बताया कि यह हथियार कई क्वार्टरल गैरेशन में उपलब्ध होगा, जिसमें तारा-250 लगभग 308 किलोग्राम के वजन के साथ जबकि तारा-450/500 का वजन लगभग 546 किलोग्राम होगा। मॉड्यूलर ग्लाइड और ग्लाइड विंड का वजन लगभग 98 किलोग्राम है, जिसमें प्रमुख संरचनात्मक संशोधनों के बिना मौजूदा बम इन्वेंटरी के साथ एकीकरण संभव हो जाता है।

एनआईए मामलों की सुनवाई में तेजी

भाविनी मिश्रा
नई दिल्ली, 8 मई

सर्वोच्च न्यायालय ने राष्ट्रीय अन्वेषण अधिकांश (एनआईए) अभियान के तहत गठित विशेष अदालतों में एनआईए की सुनवाई में तेजी लाने के उद्देश्य से शुक्रवार को कई दिशानिर्देश जारी किए। न्यायालय ने आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्ते और न्यायिक व्यय को आवश्यकता पर जोर दिया। मुख्य न्यायाधीश जयमूर्ति सूर्य कोत और न्यायमूर्ति जयमलया बाघोचें को अनुआईए दफ्ते में नई निर्देश दिए कि उच्च न्यायालय के

अधिकार क्षेत्र में लॉन्च 10 से 15 मुकदमों के लिए कम से कम एक विशेष एनआईए अदालत स्थापित की जानी चाहिए। सुनान के साथ शुरू की गई एक कमेटी के चार चार किए गए। इसका उद्देश्य नैकानूनी गतिविधियों (रोकथाम) अभियान सलित न्यायालय में आतंकवाद विरोधी कानूनों से जुड़े मामलों के लिए समर्पित सुनवाई दफ्ते और न्यायिक व्यय को आवश्यकता पर जोर दिया। अतिरिक्त अदालतों को स्थापना के लिए खास दफ्ते को स्पष्ट करत हुए पीठ ने कहा कि लंबित मुकदमों को संख्या 1.5 से अधिक होने पर दो विशेष अदालतें स्थापित की जानी



चाहिए। अगर लंबित मामलों की संख्या 2.5 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए। अगर लंबित मामलों की संख्या 2.5 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए। अगर लंबित मामलों की संख्या 2.5 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए। अगर लंबित मामलों की संख्या 2.5 के पार पहुंच गई है तो तीन ऐसे अदालतें स्थापित की जानी चाहिए।

सुनिश्चित करने के लिए संबंधित उच्च न्यायालयों के साथ समन्वय करने को कहा है। पीठ ने कहा, 'हम संबंधित अधिकारियों से उच्च न्यायालयों के साथ परामर्श करने और विशेष अदालतों के कर्मचारियों के लिए पर्याप्त जगह उपलब्ध करने का अनुरोध करते हैं। वहां पीठान्तर्गत अधिकारी इस अभियान की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालेंगे। राष्ट्रीय अन्वेषण अधिकांश अभियान की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालेंगे। राष्ट्रीय अन्वेषण अधिकांश अभियान की धारा 11 के तहत केवल मामलों को सुनवाई का कार्यभार संभालेंगे।

Progress ... Powered by innovation Proven by results

SENATOR LUXE CERA

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2026

(₹ In Lakhs)

Sr. No.	Particulars	Quarter Ended 31.03.2026 (Audited)	Year Ended 31.03.2026 (Audited)	Quarter Ended 31.03.2025 (Audited)
1	Total Income from Operations	64,381.58	2,05,011.98	5,777.96
2	Net Profit / (Loss) for the period (before Tax, Exceptional Items)	9,285.42	27,691.93	1,050.79
3	Exceptional Items	1,045.29	(780.68)	(950.43)
4	Net Profit / (Loss) for the period before Tax (after Exceptional Items)	10,350.71	26,911.25	1,080.67
5	Net Profit / (Loss) for the period after Tax (after Exceptional Items)	7,713.59	20,418.56	858.28
6	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	7,689.41	20,540.47	858.413
7	Equity Share Capital (Face value of ₹ 5/- each)	644.88	644.88	644.88
8	Other Equity (Excluding revaluation reserve) as shown in the Audited Balance Sheet of the previous year	146,588.97		
9	Earnings per equity share of ₹ 5/- each (EPS) for the quarter not annualised:			
	(1) Basic (₹)	59.96	158.31	66.36
	(2) Diluted (₹)	59.96	158.31	66.36

Notes
 1 The above is an Extract of the detailed format of Audited financial results for quarter and year ended on 31st March, 2026 filed with the Stock Exchanges under Regulation - 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited financial results for the quarter and year ended 31st March, 2026 are available on the website of the Stock Exchange (www.bseindia.com & www.nseindia.com) and the Company's website (www.cera-india.com).
 2 During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company had recognised a provision of ₹ 1,845.97 lakhs towards incremental past service cost for gratuity and leave liabilities, disclosed as an exceptional item. Pursuant to subsequent clarifications, professional advice and actuarial valuation, the liability as at March 31, 2026 has been reassessed at ₹ 780.68 lakhs. Accordingly, excess provision of ₹ 1,065.29 lakhs has been reversed during the March 2026 quarter under exceptional items. The net impact of the reassessment has been duly recognised in the statement of profit and loss.
 3 During the quarter ended March 2025, the Company entered into an amicable settlement with Ms. Mita Tilo LLP and exited the partnership. Consequently, the entire investment of ₹ 8,05,00,000 lakhs was written off (including ₹ 1,50,43,000 lakhs received during the March 2025 quarter, and disclosed as an exceptional item).
 4 Figures of the previous periods have been regrouped/ reclassified/ restated wherever necessary to conform to the current period presentation.
 5 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 08.05.2026.
 Date : 8th May, 2026
 Place : Ahmedabad

By Order of the Board of Directors
For, Cera Sanitaryware Limited
 Anupam Gupta
 Executive Director (Technical)
 (DIN: 05230850)

Cera Sanitaryware Limited
 Registered Office & Works: 9, GIDC Industrial Estate, Kadi 382715, District Mehsana, Gujarat
 CIN: L26911GJ1998PLC034400 Tel: (02764) 242329, 243000. E-mail: kadi@cera-india.com Website: www.cera-india.com

‘क्रूज में सवार भारतीय संक्रमित नहीं’

हंटावायरस के संक्रमण पर स्वास्थ्य मंत्रालय रख रहा बारीकी से नजर

संकेत कौल
नई दिल्ली, 8 मई

हंटावायरस संक्रमण के मामलों की निगरानी के लिए स्वास्थ्य मंत्रालय सक्रिय हो गया है। इसने एकियाती उपग्रह संकेतों निर्देश जारी किए हैं। सूत्रों के अनुसार एचवी बीडीएस क्रूज जहाज पर हंटावायरस संक्रमण के मामलों को पता चलने के बाद यह कदम उठाया गया है, क्योंकि जहाज पर इस खतरनाक वायरस का संक्रमण फैला गया है, उसमें दो भारतीय भी सवार हैं। मंत्रालय राष्ट्रीय रोग निरोधक केंद्र, एकीकृत रोग निगरानी कार्यक्रम, विश्व स्वास्थ्य संगठन और अन्य अंतरराष्ट्रीय स्वास्थ्य अधिकारियों के साथ समन्वय में स्थिति पर बारीकी से नजर रख रहा है।



एचवी बीडीएस क्रूज से स्थिति हंटावायरस संक्रमण के एक मरीज (दूसरी बाईं ओर) को शिफाले हवाई अड्डे पर उतार कर अस्पताल ले जाया गया

मौजूद तीन यात्रियों को मौत इस वायरस के संक्रमण से होने की बात कही गई है। एक चर्चित अधिकारी ने बताया कि अंतरराष्ट्रीय स्वास्थ्य नियामकों से मिली जानकारी से पता चला है कि दो भारतीय नागरिक भी इस जहाज पर सवार हैं। अधिकारी ने कहा, 'दोनों

यात्रि वर्गमान में अमिस्टमैटिक (स्पॉन्सिभूय) हैं और दोनों को अंतरराष्ट्रीय स्वास्थ्य प्रोटोकॉल के तहत निगरानी में रखा गया है।' एकियाती उपग्रहों के मद्देनजर राष्ट्रीय रोग निरोधक केंद्र के तहत आने वाले सांकेतिक स्वास्थ्य आपातकालीन संचालन केंद्र ने स्थिति का आकलन करने और तैयारियों को समीक्षा के लिए संबंधित विभागों और राज्यों को बंधित अधिकारियों के साथ उच्च-स्तरीय समीक्षा बैठक की है। अधिकारी ने कहा, 'केंद्रीय स्वास्थ्य मंत्रालय पूरी तरह सचेतना बरत रहा है। चर्च इन्क्यूबेचओ तथा अन्य अंतरराष्ट्रीय एजेंसियों के साथ मिलकर इससे निपटने के लिए काम कर रहा है।' सूत्रों ने यह भी बताया कि भारतीय नागरिकों के स्वास्थ्य और सुरक्षा के लिए सभी उपाय किए जा रहे हैं। इन्क्यूबेचओ के अनुसार, जहाज पर सक्रिय हुआ वायरस हंटावायरस का एंडीज स्ट्रेन है, जिसके मानव से मानव में फैलने की क्षमता कम होती है। यह तभी प्रभावित करता है जब कोई बहुत लंबे समय तक इसके संपर्क में रहे।

KALYAN JEWELLERS INDIA LIMITED
 Registered Office: TC-32/204/2, Sitaram Mill Road, Punnkunam, Thrissur, Kerala - 680 002
 CIN: L36911KL2009PLC024641
 Tel: +91 487 24 37 333 | E-mail: compliance@kalyanjewellers.net | Website: www.kalyanjewellers.net

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

₹ in Millions

Particulars	Standalone			Consolidated		
	For the quarter ended		For the year ended	For the quarter ended		For the year ended
	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)	31 March 2026 (Audited)	31 December 2025 (Unaudited)	31 March 2025 (Audited)
1 Total Income from operations (including other income)	90,463.53	91,220.63	53,927.52	3,12,625.29	2,17,871.41	1,03,211.02
2 Net profit / (loss) for the period before tax before exceptional items	4,953.49	3,825.78	2,494.15	17,739.14	9,322.65	5,388.19
3 Net profit / (loss) for the period before tax after exceptional items	4,953.49	5,410.76	2,494.15	17,324.12	9,322.65	5,388.19
4 Net profit / (loss) for the period after tax after exceptional items	3,656.48	4,008.13	1,853.70	12,851.26	6,886.82	4,095.03
5 Total comprehensive income for the period (comprising profit for the period (after tax) and other comprehensive income (after tax))	4,990.19	3,749.16	2,261.81	15,140.85	7,131.81	5,938.91
6 Equity share capital (Face value of ₹10 each)	10,327.40	10,326.63	10,314.35	10,327.40	10,314.35	10,326.63
7 Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the year	-	-	-	50,878.09	37,458.23	-
8 Basic (in ₹) (not annualised for the quarter ended)	3.54	3.88	1.80	12.45	6.68	3.97
9 Diluted (in ₹) (not annualised for the quarter ended)	3.53	3.88	1.80	12.42	6.68	3.95

Note:
 1 The above is an extract of the detailed format of the financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the BSE Listed website (URL: www.bseindia.com/corporate), the National Stock Exchange of India Limited website (URL: www.nseindia.com/corporate) and on the Company's website.

For and on behalf of the BOARD OF DIRECTORS
 T.S. Kalyanram
 Managing Director
 DIN: 01021928

